

CITATION REPORT

List of articles citing

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

DOI: 10.1056/nejmoa1603827

New England Journal of Medicine, 2016, 375, 311-22.

Source: <https://exaly.com/paper-pdf/65240728/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2261	Balancing on the tightrope of type 2 diabetes control. 2016 , 27, 606-608		
2260	Cardiovascular pharmacotherapy-2015 was a good year. 2016 , 2, 209-11		
2259	The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial and Its Clinical Impact on Patterns of Prescription for Anti-Diabetes Medication. 2016 , 17, 225		
2258	AMCP Partnership Forum: Navigating Innovations in Diabetes Care. 2016 , 22, 1369-1375		
2257	Bringing patient centricity to diabetes medication access in Canada. 2016 , 8, 599-611		1
2256	The Effect of Bariatric Surgery on Diabetic Retinopathy: Good, Bad, or Both?. 2016 , 40, 354-364		24
2255	Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US. 2017 , 9, 19-29		18
2254	Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence. 2016 , 17,		29
2253	Trending topics in diabetes: Curbing sugar intake in kids, liraglutide benefits, DPP study. 2016 , 22, 32-33		
2252	Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study). 2016 , 15, 102		11
2251	Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. 2016 , 69, 1119-1125		5
2250	Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. 2016 , 40, 484-486		44
2249	Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. 2016 , 15, 162		66
2248	More Than 7 Years of Hindsight: Revisiting the FDA's 2008 Guidance on Cardiovascular Outcomes Trials for Type 2 Diabetes Medications. 2016 , 34, 173-180		24
2247	SUSTAIN-6: cardiovascular safety of a once-weekly GLP-1 receptor agonist. 2016 , 33, 266-268a		2
2246	London buses: A cardiovascular outcome trial equivalent?. 2016 , 13, 382-383		
2245	DTB Select: 9 September 2016. 2016 , 54, 98-101		

2244	Kardiovaskuläres Outcome unter Semaglutid. 2016 , 12, 582-583	0
2243	LEADER-Studie: 22 %ige Senkung der kardiovaskulären Mortalität. 2016 , 10, 339-340	
2242	BASAL INSULIN 4.0: UPDATING YOUR CLINICAL PRACTICE WITH ULTRALONG-ACTING INSULINS AND INSULIN COMBINATION THERAPY. 2016 , 22, 1-25	
2241	Innovative Therapeutics: Designer Natriuretic Peptides. 2016 , 1, 557-567	35
2240	Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues. 2017 , 16, 227-236	14
2239	Are Diabetes Care Providers Too Gluco-centric?. 2016 , 40, 479-481	3
2238	How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 2016 , 471-492	
2237	Non-Insulin Parenteral Therapies. 2016 , 455-470	
2236	Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study. 2016 , 15, 105	40
2235	Is Liraglutide Associated With Myocardial Protection in ST-Elevation Myocardial Infarction?. 2016 , 9,	
2234	Quelle place pour les nouveaux antidiabétiques dans la prise en charge du diabète du sujet âgé?. 2016 , 10, 574-580	
2233	[Improvement in cardiovascular prognosis of type 2 diabetes mellitus, is it a reality?]. 2016 , 33, 123-125	
2232	Glucagon-like Peptide 1 Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic Enzymes. 2016 , 17, 2845-2856	18
2231	Comentarios a la guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardíaca aguda y crónica. 2016 , 69, 1119-1125	15
2230	Reflections on changing paradigms. 2016 , 33, 1011-2	1
2229	Semaglutide ed esiti cardiovascolari in pazienti con diabete di tipo 2. 2016 , 17, 270-271	
2228	LEADER and the new "cardiovascular" glucose-lowering agents. 2016 , 33, 187-189	1
2227	Is diabetes still a state of premature cardiovascular death?. 2016 , 33, 285-290	1

2226	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. 2016 , 118, 1830-43	46
2225	Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. 2016 , 39, 2042-2050	66
2224	Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. 2016 , 121, 204-214	33
2223	Current drugs for weight loss. 2016 , 33, 229-232	
2222	Cardiovascular pharmacotherapy. 2016 , 224, 412-415	
2221	Renoprotection in LEADER and EMPA-REG OUTCOME. 2016 , 4, 812-4	9
2220	Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes?. 2016 , 40, 379-381	1
2219	Current perspectives on cardiovascular outcome trials in diabetes. 2016 , 15, 139	51
2218	Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance. 2016 , 37, 554-583	39
2217	Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus. 2016 , 16, 116	33
2216	Albiglutide: a unique GLP-1 receptor agonist. 2016 , 16, 1557-1569	11
2215	Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places. 2016 , 26, 1071-1078	12
2214	Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning. 2016 , 112, 669-676	59
2213	Impact of EMPA-REG OUTCOME on the management of type 2 diabetes mellitus: a review for primary care physicians. 2016 , 128, 822-827	
2212	New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun. 2016 , 69, 1005-1007	
2211	Insulin degludec + liraglutide: a complementary combination. 2016 , 16, 1171-7	1
2210	Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells. 2016 , 436, 240-9	22
2209	Drugs for hypercholesterolaemia - from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition. 2016 , 16, 353-7	8

2208	Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. 2016 , 18, 1217-1225	30
2207	Treatment of diabetes: Crossing to the other side. 2016 , 57, 304-310	11
2206	Omarigliptin for the treatment of type 2 diabetes mellitus. 2016 , 17, 1947-52	14
2205	Investigational glucagon-like peptide-1 agonists for the treatment of obesity. 2016 , 25, 1167-79	15
2204	Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies. 2016 , 18, 1253-1262	8
2203	Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease. 2016 , 68, 985-95	34
2202	Glucagon and heart in type 2 diabetes: new perspectives. 2016 , 15, 123	42
2201	Glucagon-Like Peptide-1 Receptor Agonists and Diabetic Cardiovascular Disease: Implications of the LEADER Study. 2016 , 14, 375-377	2
2200	Glycaemic control and cardiovascular disease: is there a light at the end of the tunnel?. 2017 , 110, 421-423	3
2199	What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?. 2016 , 16, 94	1
2198	Cardiometabolic Syndrome and Increased Risk of Heart Failure. 2016 , 13, 219-229	22
2197	Diabetes News. 2016 , 8, 748-752	1
2196	Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. 2016 , 15, 111	40
2195	Liraglutide, GLP-1 receptor agonist, for chronic weight loss. 2016 , 11, 373-378	3
2194	Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. 2016 , 90, 1175-1183	73
2193	Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. 2016 , 15, 77-83	22
2192	Pharmacological Interventions against Obesity: Current Status and Future Directions. 2016 , 32, 347-351	5
2191	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 1834-1844	59.2 2547

2190	Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. 2016 , 12, 1267-1271	7
2189	GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?. 2016 , 4, 963-964	15
2188	Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. 2016 , 4, 1004-1016	249
2187	Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. 2016 , 59, 2588-2593	74
2186	Therapy: Gastrointestinal safety of incretin therapies: are we there yet?. 2016 , 13, 630-632	4
2185	Latest clinical research. 2016 , 2016, 16-17	
2184	Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial. 2016 , 7, 601-609	9
2183	Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial. 2016 , 18, 1191-1198	23
2182	Diabetes: Time for reconciliation between cardiologists and diabetologists. 2016 , 13, 509-10	6
2181	Nuevos tratamientos para la diabetes mellitus tipo 2 y enfermedad cardiovascular. La revoluci3n ya ha empezado. 2016 , 69, 1005-1007	1
2180	Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?. 2016 , 18, 671-673	1
2179	[The new ESC Guidelines for acute and chronic heart failure 2016]. 2016 , 41, 655-663	16
2178	Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD. 2016 , 11, 2104-2106	1
2177	Cardiovascular Outcomes of New Medications for Type 2 Diabetes. 2016 , 18, 749-758	6
2176	Liraglutide restores angiogenesis in palmitate-impaired human endothelial cells through PI3K/Akt-Foxo1-GTPCH1 pathway. 2016 , 86, 95-101	17
2175	Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet. 2016 , 18, 79	5
2174	Implications of the EMPA-REG Trial for Clinical Care and Research. 2016 , 16, 131	4
2173	An update on DPP-4 inhibitors in the management of type 2 diabetes. 2016 , 21, 409-419	36

2172	A Plethora of GLP-1 Agonists: Decisions About What to Use and When. 2016 , 16, 120		13
2171	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 1798-9	59.2	48
2170	Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink. 2016 , 355, i5340		9
2169	Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK. 2016 , 6, e012801		35
2168	Dulaglutid: GLP-1-Rezeptoragonist zur einmal wahentlichen Therapie des Typ-2-Diabetes. 2016 , 11, 398-417		1
2167	Relevance of weight in the management of patients with type 2 diabetes mellitus: towards an adipocentric approach to diabetes. 2016 , 147 Suppl 1, 8-16		2
2166	Hypertension in type 2 diabetes: impact of glucose-lowering medications. 2016 , 5, 137-143		
2165	Characteristics and outcomes of diabetic patients with an implantable cardioverter defibrillator in a real world setting: results from the Israeli ICD registry. 2016 , 15, 160		3
2164	Zwei Studien, die die Diabeteswelt verandern. 2016 , 10, 46-47		
2163	Diabetes medications improve cardiovascular outcomes: the paradigm shifts. 2016 , 27, 633-635		
2162	Diabetes remission off medications is not a suitable endpoint for comparing bariatric/metabolic surgery with pharmacotherapy. 2016 , 59, 2040-1		4
2161	Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?. <i>New England Journal of Medicine</i> , 2016 , 375, 380-2	59.2	26
2160	Blood pressure control in type 2 diabetic patients. 2017 , 16, 3		44
2159	Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. 2017 , 40, 325-331		26
2158	Medical Management of Diabetes: Do We Have Realistic Targets?. 2017 , 17, 4		26
2157	Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes. 2017 , 27, 375-377		4
2156	Antidiabetic agents and cardiovascular outcomes in patients with heart diseases. 2017 , 33, 985-992		7
2155	Glomerular disease in 2016: New advances in the treatment of glomerular disease. 2017 , 13, 65-66		2

2154	Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?. 2017 , 9, 6	12
2153	Liraglutide in heart failure: caution is needed. 2017 , 19, 78-79	4
2152	Cardiovascular safety and benefits of GLP-1 receptor agonists. 2017 , 16, 351-363	25
2151	Early detection of left ventricular dysfunction in first-degree relatives of diabetic patients by myocardial deformation imaging: The role of endothelial glycocalyx damage. 2017 , 233, 105-112	16
2150	The year in cardiology 2016: prevention. 2017 , 38, 542-549	1
2149	Treatment options to prevent diabetes in subjects with prediabetes: Efficacy, cost effectiveness and future outlook. 2017 , 70, 192-195	3
2148	The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients. 2017 , 124, 1-10	13
2147	[Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice]. 2017 , 34, 24-40	2
2146	Response to: Drug therapy for ectopic fat: myth or reality?. 2017 , 15, 73-74	
2145	Liraglutide for weight management: a critical review of the evidence. 2017 , 3, 3-14	110
2144	Non-alcoholic fatty liver disease and diabetes. 2017 , 148, 33-38	2
2143	An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment. 2017 , 135, 180-195	23
2142	Cardiovascular consequences of metabolic syndrome. 2017 , 183, 57-70	172
2141	Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. 2017 , 19, 7	36
2140	Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. 2017 , 16, 6	66
2139	[Cardiovascular safety concerns of glucose-lowering drugs]. 2017 , 159, 62-66	
2138	The effects of liraglutide in mice with diet-induced obesity studied by metabolomics. 2017 , 233, 93-104	16
2137	Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom. 2017 , 8, 129-147	15

2136	Un traitement par liraglutide chez un patient diabétique de type 2 ^ haut risque cardiovasculaire. 2017 , 56, 14-17	
2135	Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. 2017 , 43, 99-109	27
2134	Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway. 2017 , 7, 41085	18
2133	Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes. 2017 , 16, 387-396	11
2132	Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. 2017 , 19, 906-908	59
2131	Selection of the Best of 2016 in Vascular Risk and Cardiac Rehabilitation. 2017 , 70, 128-129	
2130	Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. 2017 , 16, 18	34
2129	Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery. 2017 , 112, 106-122	12
2128	American Diabetes Association Standards of Medical Care in Diabetes 2017. 2017 , 9, 320-324	255
2127	Exenatide: pharmacokinetics, clinical use, and future directions. 2017 , 18, 555-571	39
2126	Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. 2017 , 19, 901-905	31
2125	Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?. 2017 , 317, 1017-1018	65
2124	[Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased]. 2017 , 58, 293-302	
2123	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. 2017 , 5, 391-402	42
2122	Impact of Diabetes Mellitus on Long-Term Mortality in Patients Presenting for Coronary Angiography. 2017 , 119, 1141-1145	6
2121	SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs. 2017 , 10, 429-442	13
2120	Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. 2017 , 19, 831-841	60
2119	Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes. 2017 , 19, 850-857	12

2118	Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting. 2017 , 19, 842-849	15
2117	Evaluation of large-scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs. 2017 , 8, 633-634	2
2116	Liraglutide causes large and rapid epicardial fat reduction. 2017 , 25, 311-316	99
2115	Diabète de type 2 : concilier Médecine de Précision et Primitif des Soins de Premier recours. Pas simple !: Quid du rôle des diabétologues et de l'hôpital ?. 2017 , 11, 5-7	1
2114	Pharmacotherapy of 'treatment resistant' type 2 diabetes. 2017 , 18, 503-515	17
2113	Looking Back at Look AHEAD Through the Lens of Recent Diabetes Outcome Trials. 2017 , 135, 720-723	6
2112	Cardiac Effects of Sulfonylurea-Related Hypoglycemia. 2017 , 40, 663-670	21
2111	Basal Glucose Can Be Controlled, but the Prandial Problem Persists-It's the Next Target!. 2017 , 40, 291-300	19
2110	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. 2017 , 389, 1399-1409	324
2109	Hypoglycaemia in patients with diabetes mellitus and renal impairment. 2017 , 14, 166-168	3
2108	Continuous Glucose Monitoring in 2016. 2017 , 19, S11-S18	3
2107	GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. 2017 , 10, 401-408	33
2106	[Cardiovascular effects of liraglutide therapy in patients with type 2 diabetes : Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER)]. 2017 , 58, 303-306	
2105	Tendencias de la mortalidad por diabetes en España: por el buen camino. 2017 , 70, 421-422	1
2104	Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice. 2017 , 29, 69-85	4
2103	The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors. 2017 , 27, 194-202	28
2102	Obesity Week 2016 Annual Meeting. 2017 , 9, 215-218	
2101	The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy. 2017 , 34, 638-657	3

2100	Are diabetes guidelines truly evidence based?. 2017 , 127, 70-79		3
2099	Selection of the Best of 2016 in Diabetes and Heart. 2017 , 70, 124-125		
2098	Challenges with Evidence-Based Management of Stable Ischemic Heart Disease. 2017 , 19, 11		5
2097	Intestinal gluconeogenesis: another weight loss-independent antidiabetic effect of metabolic surgery. 2017 , 13, 630-631		
2096	Obesity-related, metabolic asthma: a new role for glucagon-like peptide 1 agonists. 2017 , 5, 162-164		7
2095	Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. 2017 , 19, 1233-1241		103
2094	Vascular risk in obesity: Facts, misconceptions and the unknown. 2017 , 14, 2-13		19
2093	Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experience. 2017 , 4, 9		7
2092	Management of Type 2 Diabetes in 2017: Getting to Goal. 2017 , 317, 1015-1016		87
2091	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017 , 376, 891-2	59.2	49
2090	Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain. 2017 , 8, 401-415		13
2089	Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing Study. 2017 , 34, 674-685		8
2088	Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential. 2017 , 6, 89-99		16
2087	Type 2 diabetes. 2017 , 389, 2239-2251		935
2086	Practical Use of Pharmacotherapy for Obesity. 2017 , 152, 1765-1779		44
2085	SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. 2017 , 12, 700-710		118
2084	[Diabetology as an interdisciplinary challenge]. 2017 , 58, 329-335		2
2083	Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. 2017 , 16, 31		45

2082	Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. 2017 , 19, 25	1
2081	Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip. 2017 , 241, 302-310	18
2080	Editorial commentary: New drugs for diabetes: Finally safety and cardiovascular efficacy. 2017 , 27, 376-377	
2079	Dulaglutide for the treatment of type 2 diabetes. 2017 , 17, 485-496	20
2078	Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. 2017 , 10, 535-547	13
2077	Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomized double-blind placebo-controlled clinical trial. 2017 , 19, 1040-1044	18
2076	Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. 2017 , 31, 1215-1221	25
2075	Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs. 2017 , 17, 203-215	4
2074	Response by Lee and Ovbiagele to Letter Regarding Article, "Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis". 2017 , 48, e136	
2073	Tolerance Does Not Develop Toward Liraglutide's Glucose-Lowering Effect. 2017 , 102, 2335-2339	4
2072	Kardiovaskulär wirksame Therapie bei Patienten mit Diabetes mellitus. 2017 , 13, 100-107	1
2071	Strategien zur Gewichtsreduktion bei Typ-2-Diabetes. 2017 , 13, 123-136	
2070	[Diabetes and heart failure : Update 2017]. 2017 , 42, 329-340	0
2069	Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. 2017 , 18, 23	49
2068	Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice. 2017 , 261, 44-51	53
2067	Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes. 2017 , 26, 1133-1141	8
2066	Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system. 2017 , 19, 1555-1561	17
2065	Heart, lipids and hormones. 2017 , 6, R59-R69	7

2064	Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy. 2017 , 59, R1-R10	35
2063	Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies. 2017 , 40, 706-714	115
2062	Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials. 2017 , 8, 587-599	9
2061	Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy. 2017 , 19, 1339-1352	28
2060	Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials. 2017 , 19, 1327-1328	13
2059	Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. 2017 , 19, 1353-1362	88
2058	Primary care diabetes prescribing rates: latest analysis shows continued rise in volume and cost. 2017 , 34, 30-33	1
2057	After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?. 2017 , 43 Suppl 1, 2S3-2S12	21
2056	GLP-1 receptor agonists and heart failure in diabetes. 2017 , 43 Suppl 1, 2S13-2S19	37
2055	Absolute benefits of empagliflozin in type 2 diabetes: a game changer?. 2017 , 93, 373-375	3
2054	[Diabetes and the central nervous system]. 2017 , 88, 675-690	1
2053	Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease. 2017 , 66, 2310-2315	17
2052	Letter by Castilla-Guerra et al Regarding Article, "Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis". 2017 , 48, e135	
2051	Dyslipidaemia in type 2 diabetes mellitus: bad for the heart. 2017 , 32, 422-429	18
2050	Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. 2017 , 56, 1391-1401	26
2049	Guideline: In type 2 diabetes, ACP recommends metformin monotherapy if drugs are needed for glycemic control. 2017 , 166, JC39	4
2048	Review: Sulfonylureas are associated with overall mortality and CV events vs other antihyperglycemics in T2DM. 2017 , 166, JC40	
2047	DPP4 inhibitors and cardiovascular outcomes: safety on heart failure. 2017 , 22, 299-304	16

2046	Macrophage functions in lean and obese adipose tissue. 2017 , 72, 120-143	141
2045	Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials. 2017 , 240, 414-421	29
2044	Using genetics to inform new therapeutics for diabetes. 2017 , 12, 159-169	
2043	Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. 2017 , 40, 966-972	41
2042	Glucose kinetics: an update and novel insights into its regulation by glucagon and GLP-1. 2017 , 20, 300-309	10
2041	Glucagon-Like Peptide 1 Receptor Activation Augments Cardiac Output and Improves Cardiac Efficiency in Obese Swine After Myocardial Infarction. 2017 , 66, 2230-2240	19
2040	A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. 2017 , 33, 940-942	4
2039	Prevention, diagnosis, and treatment of obesity. 2016 position statement of the Spanish Society for the Study of Obesity. 2017 , 64, 15-22	4
2038	Metabolic Surgery in a Pill. 2017 , 25, 985-987	7
2037	Lack of effect of prolonged treatment with liraglutide on cardiac remodeling in rats after acute myocardial infarction. 2017 , 93, 1-12	10
2036	Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease. 2017 , 28, 2263-2274	45
2035	Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China. 2017 , 19, 1688-1697	6
2034	Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. 2017 , 40, 839-848	33
2033	Are targeted therapies for diabetic cardiomyopathy on the horizon?. 2017 , 131, 897-915	48
2032	A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. 2017 , 19, 1645-1654 ²¹	
2031	GLP-1 receptor agonist confer target organ protection in type 2 diabetes. 2017 , 43 Suppl 1, 2S1-2S2	3
2030	Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. 2017 , 31, 1188-1196	37
2029	The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. 2017 , 43 Suppl 1, 2S20-2S27	41

2028	Heart failure. 2017 , 390, 1981-1995	306
2027	Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. 2017 , 18, 843-851	14
2026	Neurological outcomes of antidiabetic therapy: What the neurologist should know. 2017 , 158, 60-66	3
2025	Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose?. 2017 , 18, 839-841	11
2024	Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial. 2017 , 69, 511-517	6
2023	Post-transplantation diabetes: Treatment à la carte?. 2017 , 43, 378-381	2
2022	Perivascular adipose tissue as a regulator of vascular disease pathogenesis: identifying novel therapeutic targets. 2017 , 174, 3411-3424	38
2021	Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis. 2017 , 43, 1-8	27
2020	Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study). 2017 , 40, 194-200	43
2019	Obesity. 2017 , 3, 17034	464
2018	EMPA-REG OUTCOME: The Endocrinologist's Point of View. 2017 , 120, S48-S52	2
2017	Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome. 2017 , 130, 1068-1075	1
2016	[Cardiovascular Effects of Antidiabetic Therapies]. 2017 , 142, 737-745	1
2015	Human Epicardial Fat Expresses Glucagon-Like Peptide 1 and 2 Receptors Genes. 2017 , 49, 625-630	40
2014	Guidelines on the management of arterial hypertension and related comorbidities in Latin America. 2017 , 35, 1529-1545	36
2013	Diabetic Kidney Disease: Challenges, Progress, and Possibilities. 2017 , 12, 2032-2045	739
2012	Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes. 2017 , 43, 299-313	16
2011	Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. 2017 , 71, e12948	14

2010	Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists. 2017 , 39, 1244-1264	9
2009	Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. 2017 , 19, 62	3
2008	Multitype Events and the Analysis of Heart Failure Readmissions: Illustration of a New Modeling Approach and Comparison With Familiar Composite End Points. 2017 , 10,	2
2007	Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide. 2017 , 39, 1347-1359	15
2006	Cardiovascular safety of noninsulin antidiabetic drugs: Facts and promises. 2017 , 217, 473-477	
2005	Planning secondary prevention: Room for improvement. 2017 , 24, 22-28	12
2004	We Know More Than We Can Tell About Diabetes and Vascular Disease: The 2016 Edwin Bierman Award Lecture. 2017 , 66, 1735-1741	12
2003	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. 2017 , 40, 813-820	78
2002	Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. 2017 , 40, 821-831	48
2001	Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity. 2017 , 13, 891-896	4
2000	Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. 2017 , 19, 1610-1619	98
1999	The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL. 2017 , 16, 66	9
1998	The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease. 2017 , 31, 311-318	7
1997	Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials. 2017 , 32, 1044-1051	17
1996	Advances in Clinical Cardiology 2016: A Summary of the Key Clinical Trials. 2017 , 34, 1503-1527	4
1995	Urinary sodium excretion after gastric bypass surgery. 2017 , 13, 1506-1514	15
1994	Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial. 2017 , 19, 1818-1822	14
1993	Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. 2017 , 120, S28-S36	30

1992	Novel Diabetes Drugs and the Cardiovascular Specialist. 2017 , 69, 2646-2656	64
1991	GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?. 2017 , 66, 1453-1460	36
1990	Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. 2017 , 130, S4-S17	59
1989	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. 2017 , 130, S18-S29	37
1988	Diabetes Mellitus and Heart Failure. 2017 , 130, S40-S50	77
1987	A review on cardiovascular effects of newer hypoglycaemic medications. 2017 , 49, 603-612	9
1986	Revascularization for patients with diabetes mellitus and stable ischemic heart disease: an update. 2017 , 32, 608-616	1
1985	American Association of Clinical Endocrinologists 2017. 2017 , 9, 817-820	2
1984	Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1 α in Patients With Type 2 Diabetes. 2017 , 40, 1073-1081	71
1983	EMPA-REG OUTCOME: The Endocrinologist's Point of View. 2017 , 130, S51-S56	3
1982	Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. 2017 , 130, S30-S39	42
1981	Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes. 2017 , 37, 927-943	11
1980	Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials. 2017 , 40, 1251-1258	33
1979	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. 2017 , 120, S17-S27	54
1978	[Post-transplantation diabetes mellitus in kidney recipients]. 2017 , 13 Suppl 1, S137-S146	
1977	Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. 2017 , 74, 719-728	80
1976	So Many Antihyperglycemics: How to Choose? A Practical Approach. 2017 , 41, 469-473	3
1975	Metabolic Recovery of the Failing Heart: Emerging Therapeutic Options. 2017 , 13, 25-28	2

1974	A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist. 2017 , 12, 2107-2116	15
1973	The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype. 2017 , 60, 1801-1812	50
1972	Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. 2017 , 120, S4-S16	41
1971	Diabetes Mellitus and Heart Failure. 2017 , 120, S37-S47	98
1970	Use of lorcaserin for glycemic control in patients with type 2 diabetes mellitus. 2017 , 25, 816	1
1969	Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice. 2017 , 17, 34	28
1968	Trends in Mortality From Diabetes in Spain: On the Right Way. 2017 , 70, 421-422	
1967	Glycaemic control and weight loss with semaglutide in type 2 diabetes. 2017 , 5, 315-317	4
1966	Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes. 2017 , 10, 621-632	8
1965	Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease. 2017 , 32, 591-597	6
1964	Endothelial and Perivascular Adipose Tissue Abnormalities in Obesity-Related Vascular Dysfunction: Novel Targets for Treatment. 2017 , 69, 360-368	29
1963	Comorbidities in Heart Failure. 2017 , 243, 35-66	21
1962	SGLT2-inhibitors in type-2 diabetes: The remaining questions!. 2017 , 11 Suppl 1, S433-S438	2
1961	Non-alcoholic fatty liver disease and diabetes. 2017 , 148, 33-38	
1960	Cardiovascular safety of noninsulin antidiabetic drugs: facts and promises. 2017 , 217, 473-477	1
1959	Selection of the Best of 2016 in Clinical Cardiology: Therapeutic Novelties. 2017 , 70, 123-124	
1958	Selección de lo mejor del año 2016 en diabetes y corazón. 2017 , 70, 124-125	2
1957	Selección de lo mejor del año 2016 en cardiología clínica. Novedades terapéuticas. 2017 , 70, 123-124	

1956	Selección de lo mejor del año 2016 en riesgo vascular y rehabilitación cardiaca. 2017 , 70, 128-129		
1955	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. 2017 , 5, 355-366	180	
1954	Geographic Variations in Controlled Trials. <i>New England Journal of Medicine</i> , 2017 , 376, 1198	59.2	3
1953	Diabetes UK Professional Conference. 2017 , 9, 644-647		
1952	All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: A population-based, open cohort study. 2017 , 43, 211-216	21	
1951	Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists. 2017 , 127, 224-237	11	
1950	Mechanisms linking empagliflozin to cardiovascular and renal protection. 2017 , 241, 450-456	24	
1949	Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom. 2017 , 8, 417-431	16	
1948	Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists. 2017 , 10, 633-647	1	
1947	Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development. 2017 , 102, 290-296	9	
1946	WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. 2017 ,	1	
1945	Cardiovascular safety of liraglutide for the treatment of type 2 diabetes. 2017 , 16, 627-635	2	
1944	Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study. 2017 , 35, 1070-1078	26	
1943	Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. 2017 , 19, 1529-1536	27	
1942	Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. 2017 , 19, 1276-1288	37	
1941	CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?. 2017 , 23, 89-99	10	
1940	Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK. 2017 , 8, 513-530	15	
1939	Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms. 2017 , 40, 925-935	27	

1938	Tightening our understanding of intensive glycaemic control. 2017 , 5, 405-407	4
1937	The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations. 2017 , 129, 421-429	0
1936	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). 2017 , 187, 1-9	39
1935	Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use. 2017 , 16, 481-492	3
1934	Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials. 2017 , 49, 552-561	14
1933	Reflections on using non-inferiority randomised placebo controlled trials in assessing cardiovascular safety of new agents for treatment of type 2 diabetes. 2017 , 22, 54-56	1
1932	[Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice]. 2017 , 31, 255-268	2
1931	Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. 2017 , 166, 572-578	78
1930	Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?. 2017 , 17, 21	22
1929	Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes. 2017 , 22, 57-58	1
1928	Genetically Driven Hyperglycemia Increases Risk of Coronary Artery Disease Separately From Type 2 Diabetes. 2017 , 40, 687-693	34
1927	Cardiovascular inflammation is reduced with methotrexate in diabetes. 2017 , 432, 159-167	8
1926	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. 2017 , 5, 333-340	164
1925	Dipeptidyl peptidase-IV in chronic heart failure with reduced ejection fraction. 2017 , 241, 249-254	4
1924	Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial. 2017 , 19, 324-327	3
1923	Transitions, Introductions, and a Notable Announcement From the US FDA in December 2016. 2017 , 51, 140-141	0
1922	Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group. 2017 , 16, 35	11
1921	Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. 2017 , 16, 34	68

1920	Management of Atherosclerotic Cardiovascular Disease Risk Factors in the Older Adult Patient With Diabetes. 2017 , 40, 476-484	7
1919	The Pathophysiology of Hyperglycemia in Older Adults: Clinical Considerations. 2017 , 40, 444-452	66
1918	Is HbA 65 Years Old?. 2017 , 40, 526-528	9
1917	Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use. 2017 , 8, 365-376	33
1916	Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial. 2017 , 40, 301-308	11
1915	Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. 2017 , 47, 266-280	44
1914	Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes. 2017 , 27, 129-137	12
1913	Understanding the impact of hypoglycemia on the cardiovascular system. 2017 , 12, 21-33	18
1912	Imaging oxygen metabolism with hyperpolarized magnetic resonance: a novel approach for the examination of cardiac and renal function. 2017 , 37,	11
1911	Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?. 2017 , 49, 235-240	29
1910	Protocol of GLUCOSE COntrol Safety and Efficacy in type 2 Diabetes, a NETWORK meta-analysis: GLUCOSE DINET protocol-Rational and design. 2017 , 31, 258-264	3
1909	Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology. 2017 , 69, 501-507	22
1908	Drug therapy for ectopic fat: myth or reality?. 2017 , 15, 71-72	1
1907	The year in cardiology 2016: heart failure. 2017 , 38, 705-711	1
1906	Incretin-based therapy for type 2 diabetes: A real class effect?. 2017 , 227, 141-142	1
1905	Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes. 2017 , 8, 431-433	6
1904	Emerging drugs for the treatment of obesity. 2017 , 22, 87-99	16
1903	Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial. 2017 , 19, 509-516	24

1902	Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. 2017 , 13, 11-26	265
1901	Cardiovascular safety of incretin-based therapy for type 2 diabetes: A meta-analysis of randomized trials. 2017 , 230, 324-326	11
1900	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). 2017 , 135, 724-735	100
1899	Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide. 2017 , 56, 719-731	10
1898	8. Pharmacologic Approaches to Glycemic Treatment. 2017 , 40, S64-S74	307
1897	9. Cardiovascular Disease and Risk Management. 2017 , 40, S75-S87	174
1896	Diabetes mellitus and cardiovascular clinical characteristics of Spanish women with stable ischaemic heart disease: Data from the SIRENA study. 2017 , 123, 82-86	3
1895	Understanding and overcoming metformin gastrointestinal intolerance. 2017 , 19, 473-481	83
1894	Incretin-related drugs and cardiovascular events: A comparison of GLP-1 analogue and DPP-4 inhibitor. 2017 , 69, 508-510	2
1893	10. Microvascular Complications and Foot Care. 2017 , 40, S88-S98	110
1892	Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function. 2017 , 39, 159-169	14
1891	Liraglutide for weight management: benefits and risks. 2017 , 33, 537-539	1
1890	Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. 2017 , 28, 250-260	155
1889	Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. 2017 , 19, 734-738	12
1888	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. 2017 , 66, 241-255	292
1887	Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. 2017 , 19, 524-536	216
1886	Cardiovascular and All-Cause Mortality Risk Associated With Urinary Excretion of 8-oxoGuo, a Biomarker for RNA Oxidation, in Patients With Type 2 Diabetes: A Prospective Cohort Study. 2017 , 40, 1771-1778	36
1885	The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?. 2017 , 17, 124	13

1884	Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes. 2017 , 35, 141-153	1
1883	Response to Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1 β in Patients With Type 2 Diabetes. <i>Diabetes Care</i> 2017;40:1073-1081. 2017 , 40, e159-e160	
1882	Rezeptoragonisten des α -glucagon-like peptide 1 2017 , 13, 487-497	
1881	SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review. 2017 , 8, 1245-1251	34
1880	Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. 2017 , 41, 524-535	40
1879	The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease. 2017 , 7, 130-137	4
1878	Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes. 2017 , 60, 422-434	55
1877	Is glycemia control in Canadians with diabetes individualized? A cross-sectional observational study. 2017 , 5, e000316	5
1876	Back to Byzance: Querelles byzantines over NASH and fibrosis. 2017 , 67, 1134-1136	10
1875	Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus. 2017 , 14, 445-453	5
1874	Incretins and Their Endocrine and Metabolic Functions. 2017 , 32, 38-48	3
1873	Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors. 2017 , 13, 728-730	20
1872	Orale Triple-Therapie α -B sinnvolle Strategie oder nur Verz \ddot{u} gerungstaktik?. 2017 , 13, 416-420	
1871	Glucagon-like peptide-1 analogues in nonalcoholic steatohepatitis: From bench to bedside. 2017 , 10, 32-35	3
1870	Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. 2017 , 17, 112	18
1869	The impact of extended release exenatide as adjuvant therapy on hemoglobin A1C, weight, and total daily dose of insulin in patients with type 2 diabetes mellitus using U-500 insulin. 2017 , 134, 38-43	2
1868	Is the Way to Someone's Heart Through Their Stomach? The Cardiorenal Paradox of Incretin-Based Hypoglycemic Drugs in Heart Failure. 2017 , 10,	10
1867	Unbreakable? An analysis of the fragility of randomized trials that support diabetes treatment guidelines. 2017 , 134, 91-105	24

1866	Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. 2017 , 318, 1460-1470	211
1865	Review of the top 5 cardiology studies of 2015-16. 2017 , 150, 380-386	2
1864	Current pharmacotherapies for obesity: A practical perspective. 2017 , 29, S43-S52	9
1863	Inkretinbasierte Diabetesmedikamente. 2017 , 13, 498-504	
1862	Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF- κ B Activation. 2017 , 158, 4218-4232	26
1861	Insulin and Its Cardiovascular Effects: What Is the Current Evidence?. 2017 , 17, 120	19
1860	Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. 2017 , 136, 1643-1658	256
1859	Diabetes and CKD in the United States Population, 2009-2014. 2017 , 12, 1984-1990	74
1858	COMPARING CLINICAL OUTCOMES AND COSTS FOR DIFFERENT TREATMENT INTENSIFICATION APPROACHES IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN: ADDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS VERSUS ADDING RAPID-ACTING INSULIN OR INCREASING BASAL INSULIN DOSE. 2017 , 23, 1316-1324	5
1857	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. 2017 , 19, 1390-1400	111
1856	The shifting paradigm in the treatment of type 2 diabetes mellitus-A cardiologist's perspective. 2017 , 40, 970-973	4
1855	Current and emerging pharmacotherapies for obesity in Australia. 2017 , 11, 501-521	7
1854	Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?. 2017 , 40, 1144-1151	30
1853	Should we screen for type 2 diabetes among asymptomatic individuals? Yes. 2017 , 60, 2148-2152	13
1852	The effect of SGLT2 inhibitors on cardiovascular events and renal function. 2017 , 10, 1251-1261	9
1851	Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. 2017 , 136, 849-870	279
1850	[How to Retard Progression of Chronic Kidney Disease]. 2017 , 142, 1282-1289	1
1849	A New Chapter for Diabetic Kidney Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 885-887	59.2 16

1848	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017 , 377, 839-848	59.2	599
1847	A survey on investigation of vital human parameters from photoplethysmography signal to predict the risk of cardiovascular diseases. 2017 ,		3
1846	Prophylaxe und Therapie der diabetischen Nephropathie. 2017 , 12, 407-413		1
1845	Pharmacological control of blood sugar. 2017 , 18, 532-534		0
1844	Pharmacological management of type 2 diabetes: what's new in 2017?. 2017 , 10, 1383-1394		16
1843	NMDAR antagonists for the treatment of diabetes mellitus-Current status and future directions. 2017 , 19 Suppl 1, 95-106		12
1842	Practical Ways to Achieve Targets in Diabetes Care 2017. 2017 , 9, 978-982		
1841	Clinical significance of diabetes likely induced by statins: Evidence from a large population-based cohort. 2017 , 133, 60-68		12
1840	Pioglitazone versus sulfonylureas: cardiovascular outcomes with older diabetes drugs. 2017 , 5, 845-847		1
1839	Preventative Cardiology. 2017 , 2, 743-758		
1838	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017 , 377, 1228-1239	59.2	1017
1837	Effects of Liraglutide on Weight Loss, Fat Distribution, and β Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. 2017 , 40, 1556-1564		45
1836	A Practical Approach to Hypertension Management in Diabetes. 2017 , 8, 981-989		12
1835	Diabetes Research and Care Through the Ages. 2017 , 40, 1302-1313		7
1834	Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease. 2017 , 121, 695-710		134
1833	Decreased glucagon-like peptide 1 receptor expression in endothelial and smooth muscle cells in diabetic db/db mice: TCF7L2 is a possible regulator of the vascular glucagon-like peptide 1 receptor. 2017 , 14, 540-548		11
1832	Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus. 2017 , 31, 459-470		2
1831	GLP-1 receptor agonists: An example of the challenge for animal models to predict plaque instability/rupture and cardiovascular outcomes. 2017 , 265, 250-252		1

1830	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. 2017 , 33, 1342-1433	330
1829	Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR [®] Research to Practice project. 2017 , 24, 1637-1645	73
1828	Can we reconcile 'the obesity paradox' with recent cardiovascular outcome trials in diabetes?. 2017 , 7, 255-259	1
1827	Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure. 2017 , 6,	41
1826	Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia. 2017 , 34, 1876-1896	8
1825	Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes. 2017 , 8, 739-752	19
1824	Approaches to obesity management. 2017 , 47, 734-739	12
1823	Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions. 2017 , 17, 67	3
1822	Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus. 2017 , 125, 419-435	6
1821	Some Doubts About the Mantra on the Deleterious Cardiovascular Effects of Sulfonylureas. 2017 , 66, 2069-2071	
1820	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. 2017 , 40, 1121-1127	32
1819	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes. 2017 , 40, 1128-1132	21
1818	GLP-1/glucagon receptor co-agonism for treatment of obesity. 2017 , 60, 1851-1861	84
1817	Diabetesassozierte Nierener krankung. 2017 , 13, 365-380	
1816	Long Term Effects of Liraglutide in Japanese Patients with type 2 Diabetes Among the Subgroups with Different Renal Functions: Results of 2-Year Prospective Study. 2017 , 67, 640-646	7
1815	Individualisation du traitement de lâyperglycmie du diabe de type 2 : choix selon la classe thrapeutique, ou selon la molcule: Quel poids accorder aux rsultats des grandes tudes de scuritcardiovasculaire exigs par la FDA ?. 2017 , 11, 2S2-2S14	
1814	Nouvelles tudes dans le diabe de type 2 : le point de vue du cardiologue. 2017 , 11, 2S43-2S48	
1813	Introduction. 2017 , 130, S1-S3	8

1812	GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice. 2017 , 31, 1370-1375	2
1811	Historique des études cardiovasculaires : de lâGDPâaux derni�res études. 2017 , 11, 2S15-2S26	7
1810	S�curit�cardiovasculaire des agonistes du r�cepteur du glucagon-like peptide-1 et des inhibiteurs du co-transporteur sodium-glucose de type 2 : focus sur les r�sultats des grands essais dâintervention. 2017 , 11, 2S27-2S36	
1809	Review article: new treatments in non-alcoholic fatty liver disease. 2017 , 46, 494-507	41
1808	Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress. 2017 , 264, 1-10	43
1807	Liraglutide preserves renal function in overweight diabetic patients with stage 3 chronic kidney disease. 2017 , 44, e28-e29	6
1806	�tudes LEADER et EMPA-REG OUTCOME : implications en pratique clinique. 2017 , 11, 2S49-2S55	
1805	Agonistes du r�cepteur du GLP-1 et fonction r�nale chez le diab�tique de type 2. 2017 , 11, 272-277	
1804	[Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice]. 2017 , 43, 295-311	1
1803	Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease. 2017 , 96-98, 1-4	8
1802	iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents. 2017 , 33, 2187-2194	3
1801	Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. 2017 , 54, 933-941	40
1800	[Combination of oral antidiabetic drugs: What fits together?]. 2017 , 159, 47-52	
1799	Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. 2017 , 129, 811-821	32
1798	Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. 2017 , 16, 1121-1132	12
1797	Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost?. 2017 , 17, 71	28
1796	Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. 2017 , 26, 292-300	237
1795	Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes. 2017 , 248, 301-307	20

1794	Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. 2017 , 60, 1620-1629	231
1793	Cardiovascular disease leads to a new algorithm for diabetes treatment. 2017 , 11, 1126-1133	12
1792	60 years of metformin use: a glance at the past and a look to the future. 2017 , 60, 1561-1565	63
1791	Diabetes Update 2017. 2017 , 13, 302-312	3
1790	Dipeptidyl peptidase-4 inhibition and renoprotection: the role of antifibrotic effects. 2017 , 26, 56-66	13
1789	Hemodynamic effects by glucagon-like peptide-1 receptor analogues: what should be measured?. 2017 , 35, 953-954	0
1788	Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. 2017 , 70, 883-893	68
1787	Challenges in the Design and Interpretation of Noninferiority Trials: Insights From Recent Stent Trials. 2017 , 70, 894-903	15
1786	Metformin: new insights into an archetypal cardiometabolic drug. 2017 , 6, 92-94	
1785	Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODE) using individual participant data from randomised trials. 2017 , 5, 788-798	72
1784	Gut check on diabetes: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity. 2017 , 37, 10-15	7
1783	Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. 2017 , 40, 1425-1432	160
1782	A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data. 2017 , 31, 1719-1727	43
1781	Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes. 2017 , 6, 175-186	12
1780	Geßprotektion durch Antidiabetika über die Glukosesenkung hinaus. 2017 , 17, 43-46	
1779	With regard to the papers by Kumar et al. and de Leeuw and de Boer addressing the cardiovascular safety and efficacy of anti-diabetic drugs. 2017 , 3, 75-76	2
1778	Why Should be the Strategy of Type 2 Diabetes Treatment Radically Changed. 2017 , 24, 263-272	
1777	Semaglutid – ein neuer langwirksamer GLP-1-Rezeptor-Agonist mit nachgewiesener kardiovaskulärer Ereignisreduktion bei Typ-2-Diabetes. 2017 , 12, 141-148	

1776	Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial. 2017 , 39, 2438-2447	6
1775	Lixisenatide: A New Option for Managing Type 2 Diabetes. 2017 , 33, 195-203	4
1774	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017 , 377, 2197-2198	25
1773	Neue Antidiabetika und kardiovaskuläre Outcome-Studien. 2017 , 12, 273-285	1
1772	Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development. 2017 , 31, 399-421	2
1771	The CANVAS trial programme raises more questions than answers. 2017 , 34, 232-233	1
1770	Influence of Referral to a Combined Diabetology and Nephrology Clinic on Renal Functional Trends and Metabolic Parameters in Adults With Diabetic Kidney Disease. 2017 , 1, 150-160	10
1769	Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis. 2017 , 27, 1081-1088	16
1768	Cardiovascular safety outcomes of new antidiabetic therapies. 2017 , 74, 970-976	4
1767	Introduction. 2017 , 120, S1-S3	
1766	GLP-1 receptor agonists, carotid atherosclerosis and retinopathy. 2017 , 18, 1163-1165	3
1765	Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure. 2017 , 14, 275-283	10
1764	Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. 2017 , 43, 430-437	25
1763	Adipositas: Gibt es sinnvolle medikamentöse Therapieansätze?. 2017 , 50, 99-104	1
1762	Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting. 2017 , 17, 64	1
1761	Sex and gender differences in therapy of type 2 diabetes. 2017 , 131, 230-241	42
1760	Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus. 2017 , 167, 75-76	3
1759	Do Sugar-Sweetened Beverages Cause Obesity and Diabetes?. 2017 , 167, 72-73	

1758	Do Sugar-Sweetened Beverages Cause Obesity and Diabetes?. 2017 , 167, 71-72	1
1757	Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus. 2017 , 167, 73-74	
1756	Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus. 2017 , 167, 74-75	1
1755	Do Sugar-Sweetened Beverages Cause Obesity and Diabetes?. 2017 , 167, 72	0
1754	Antihyperglycemic agents and cardiovascular outcomes: recent insights. 2017 , 32, 642-650	2
1753	The EP3 Receptor/G Signaling Axis as a Therapeutic Target for Diabetes and Cardiovascular Disease. 2017 , 19, 1276-1283	9
1752	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. 2017 , 18, 1243-1260	30
1751	The safety of albiglutide for the treatment of type 2 diabetes. 2017 , 16, 1089-1097	4
1750	Diabetes und Zentralnervensystem. 2017 , 13, 47-62	
1749	Antidiabetika bei älteren, multimorbiden Patienten. 2017 , 13, 91-99	
1748	Renale und kardiale Effekte von SGLT2-Inhibitoren. 2017 , 12, 90-96	
1747	Positive kardiovaskuläre Endpunktstudien waren Highlights des vergangenen Jahres. 2017 , 11, 54-54	
1746	Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. 2017 , 5, 610-621	217
1745	Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials. 2017 , 31, 1415-1422	7
1744	Glucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma. 2017 , 180, 139-143	22
1743	Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. 2017 , 129, 686-697	32
1742	[Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?]. 2017 , 159, 7-15	2
1741	iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes. 2017 , 51, 990-999	7

1740	Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine. 2017 , 16, 67	11
1739	Sex difference in the risk for exercise-induced albuminuria correlates with hemoglobin A1C and abnormal exercise ECG test findings. 2017 , 16, 79	13
1738	The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg. 2017 , 9, 44	33
1737	Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study. 2017 , 3, 5	3
1736	Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball. 2017 , 19, 70	18
1735	Pioglitazone and cardiovascular risk reduction: time for a second look?. 2017 , 6, 55-61	
1734	The emergence of cardiometabolism. 2017 , 6, 3-7	1
1733	Nonalcoholic fatty liver disease: implications for cardiovascular risk. 2017 , 6, 62-72	7
1732	Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus. 2017 , 13, 311-321	3
1731	Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. 2017 , 57, 464-473	41
1730	Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus. 2017 , 8, 33-53	12
1729	Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. 2017 , 19, 356-363	35
1728	Comparative studies of insulin vs glucagon-like peptide-1 receptor agonists in patients initiating injectable therapy. 2017 , 19, 153-155	1
1727	Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. 2017 , 34, 1-40	36
1726	'Browning' the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk. 2017 , 228, 265-274	75
1725	A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?. 2017 , 228, 198-200	5
1724	Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. 2017 , 19, 336-347	120
1723	Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective. 2017 , 39, 1012-1025	12

1722	Need for Outcome Scenario Analysis of Clinical Trials in Diabetes. 2017 , 11, 327-334	1
1721	Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. 2017 , 40, 117-124	56
1720	The effect of liraglutide on renal function: A randomized clinical trial. 2017 , 19, 239-247	55
1719	Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. 2017 , 19, 436-441	42
1718	Metabolomics and Metabolic Diseases: Where Do We Stand?. 2017 , 25, 43-56	339
1717	Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes. 2017 , 28, 88-103	61
1716	Diabetes News. 2017 , 9, 111-114	
1715	Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial. 2017 , 176, 77-86	27
1714	Therapeutic Targeting of Cellular Stress to Prevent Cardiovascular Disease: A Review of the Evidence. 2017 , 17, 83-95	7
1713	Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. 2017 , 19, 69-77	230
1712	Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. 2017 , 26, 459-468	89
1711	Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. 2017 , 13, 211-223	12
1710	The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory. 2017 , 56, 509-520	41
1709	Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. 2017 , 49, 51-62	13
1708	SGLT2 Inhibitors-Sweet Success for Diabetic Kidney Disease?. 2017 , 28, 7-10	16
1707	With regard to the paper by Zannad et al. entitled Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment versus risk aversion. 2017 , 3, 7-8	4
1706	Hemoglobin A levels and risk of sudden cardiac death: A nested case-control study. 2017 , 14, 72-78	9
1705	Following the LEADER - why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes. 2017 , 31, 517-519	6

1704	Cardiovascular safety trials of incretin-based drugs: What do they mean?. 2017 , 8, 272-276	7
1703	Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. 2017 , 19, 43-53	76
1702	Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes. 2017 , 31, 449-455	37
1701	Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabetes: the real world experience. 2017 , 55, 173-178	21
1700	Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. 2017 , 43, 48-58	71
1699	A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. 2017 , 19, 216-227	83
1698	Prevention, diagnosis, and treatment of obesity. 2016 position statement of the Spanish Society for the Study of Obesity. 2017 , 64 Suppl 1, 15-22	40
1697	Cardiovascular safety of therapies for type 2 diabetes. 2017 , 16, 13-25	5
1696	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. 2017 , 33, 366-377	19
1695	A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies. 2017 , 19, 375-386	17
1694	Long-term mortality after acute myocardial infarction among individuals with and without diabetes: A systematic review and meta-analysis of studies in the post-reperfusion era. 2017 , 19, 364-374	16
1693	Meta-Analysis of Impact of Diabetes Mellitus on Outcomes After Transcatheter Aortic Valve Implantation. 2017 , 119, 623-629	13
1692	Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity. 2017 , 18, 86-98	36
1691	Adipositas und Prädabetes. 2017 , 13, 482-486	
1690	The impact of glucose-lowering medications on cardiovascular disease. 2018 , 7, 13-17	
1689	Prevalence of cardiovascular disease and evaluation of standard of care in type 2 diabetes: a nationwide study in primary care. 2017 , 6, 145-151	21
1688	DPP-4 Inhibitors Improve Diabetic Wound Healing via Direct and Indirect Promotion of Epithelial-Mesenchymal Transition and Reduction of Scarring. 2018 , 67, 518-531	38
1687	Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. 2017 , 3, 425-433	12

1686	Response to comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al. 2017 , 3, 131	1
1685	Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. 2018 , 7, 18-23	3
1684	Antidiabetic medications and mortality reduction: a shift from surrogate to clinical endpoints. 2017 , 8, 173-174	1
1683	Therapies for non-alcoholic steatohepatitis. 2017 , 1, 214-220	1
1682	Randomized Trial of the Effects of Insulin and Metformin on Myocardial Injury and Stress in Diabetes Mellitus: A Post Hoc Exploratory Analysis. 2017 , 6,	6
1681	Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens. 2017 , 35, 321-328	0
1680	Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. 2017 , 64, 269-281	54
1679	American Association of Diabetes Educators 2017. 2017 , 9, 1054-1057	1
1678	Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation. 2017 , 117, 1115-1128	35
1677	Essential and unnecessary medicines for diabetes. 2017 , 26, 59-74	
1676	Metabolische Chirurgie zur Prävention des Typ-2-Diabetes. 2017 , 13, 403-407	
1675	Empagliflozin reduziert das Risiko für Mortalität sowie makro- und mikrovaskuläre Komplikationen bei Patienten mit Typ-2-Diabetes und bestehender kardiovaskulärer Erkrankung. 2017 , 12, 294-306	
1674	Inconclusive effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. 2017 , 34, 302-303	2
1673	Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. 2017 , 357, j2499	32
1672	Gute Gründe für Sitagliptin. 2017 , 11, 59-59	
1671	Achterbahnfahrt mit Schreck und Jubel. 2017 , 11, 3-4	
1670	[Cardiovascular protection of diabetic patient with chronic renal disease and particular case of end-stage renal disease in elderly patients]. 2017 , 13, 6S16-6S24	4
1669	Effects of glucose-lowering agents on ischemic stroke. 2017 , 8, 270-277	3

1668 Blutzucker, Blutdruck und Blutfette. **2017**, 15, 142-144

1667 Highlights vom ADA 2017. **2017**, 15, 190-193

1666 The impact of antihypertensives on kidney disease. **2017**, 6, 611

3

1665 Semaglutide seems to be more effective the other GLP-1Ras. **2017**, 5, 505

18

1664 Kardiovaskuläre Risikofaktoren bei Diabetes. **2017**, 46, 324-329

1663 Role of New Therapies in Reducing Mortality and Major Morbidity in Patients with Systolic Heart Failure. **2017**,

1662 Integrating cardioprotective glucose-lowering medications into clinical practice. **2018**, 7, 24-27

1661 Management of Obesity in Patients with Diabetes Mellitus. **2017**, 18, 229

1

1660 [The safety of anti-diabetic drugs in heart failure]. **2017**, 158, 163-171

1

1659 Postprandial Hyperlipidemia and Remnant Lipoproteins. **2017**, 24, 95-109

72

1658 ROK and Arteriolar Myogenic Tone Generation: Molecular Evidence in Health and Disease. **2017**, 8, 87

12

1657 Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies. **2017**, 8, 15

19

1656 Effects of Incretin-Based Therapies on Diabetic Microvascular Complications. **2017**, 32, 316-325

9

1655 Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. **2017**, 13, 69-79

6

1654 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association. **2017**, 41, 423-429

8

1653 Analisi di Impatto Sul Budget di Empagliflozin Nel Trattamento Dei Pazienti Con Diabete di tipo 2 e Malattia Cardiovascolare Accertata. **2017**, 4, grhta.5000263

0

1652 Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. **2017**, 10, 123-139

64

1651 Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimpiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study. **2017**, 8, 325

13

1650	The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis. 2017 , 2017, 9257930	0
1649	Macrovascular Complications in Patients with Diabetes and Prediabetes. 2017 , 2017, 7839101	99
1648	New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data. 2017 , 2017, 1253425	8
1647	Lipids: A Suitable Therapeutic Target in Diabetic Neuropathy?. 2017 , 2017, 6943851	21
1646	The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice. 2017 , 18,	44
1645	Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction. 2017 , 12, 4835-4848	20
1644	Novel approaches for treating hypertension. 2017 , 6, 80	4
1643	Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. 2017 , 10, 79-87	17
1642	Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D). 2017 , 13, 1569-1576	3
1641	Reconsideration of Secondary Risk Management Strategies in Patients with Ischemic Heart Disease. 2017 , 39, 11-24	2
1640	The impact of cardiovascular co-morbidities and duration of diabetes on the association between microvascular function and glycaemic control. 2017 , 16, 114	20
1639	The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis. 2017 , 16, 122	34
1638	Updates on cardiovascular outcome trials in diabetes. 2017 , 16, 128	36
1637	Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). 2017 , 16, 137	9
1636	Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis. 2017 , 16, 143	34
1635	Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease. 2017 , 16, 227	13
1634	Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). 2017 , 9, 53	15
1633	Liraglutide attenuates atherosclerosis via inhibiting ER-induced macrophage derived microvesicles production in T2DM rats. 2017 , 9, 94	13

1632	Kardiovaskuläre Risikoreduktion durch Antidiabetika über Glukosesenkung hinaus. 2017 , 11, 32-36	1
1631	Diabetic retinopathy: research to clinical practice. 2017 , 3, 9	23
1630	Diabetes mellitus Typ 2. 2017 ,	
1629	Coronary Artery Disease and Type 2 Diabetes Mellitus. 2017 , 58, 475-480	79
1628	Herzschutz durch GLP-1-Analogon unabhängig von Komedikation und Hypoglykämie. 2017 , 11, 44-45	
1627	Kardiovaskuläre Outcome-Studien in der Diabetologie – ein Überblick. 2017 , 10, 119-121	
1626	Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists-what will REWIND add?. 2017 , 5, 476	4
1625	. 2017 , 109, 1-31	16
1624	United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes. 2017 , 11, 1209-1220	2
1623	[Management of diabetes in patients with hypertension]. 2017 , 34 Suppl 2, 30-34	1
1622	Diabetes mellitus and stroke: A clinical update. 2017 , 8, 235-248	64
1621	Recent advances in understanding/managing type 2 diabetes mellitus. 2017 , 6,	2
1620	Treatment of type 2 diabetes mellitus in the elderly. 2017 , 8, 278-285	40
1619	Antidiabetic Drugs as Antihypertensives: New Data on the Horizon. 2017 , 16, 70-78	3
1618	Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association. 2017 , 41, 337-348	38
1617	GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. 2017 , 13, 605-628	154
1616	Antihyperglycemic Medications and Cardiovascular Risk Reduction. 2017 , 13, 86-90	5
1615	Effects of glycaemic management on diabetic kidney disease. 2017 , 8, 172-186	35

- 1614 Managing problems with medications for type 2 diabetes. **2017**, 28, 148-153
- 1613 PROTOCOLOS CLÍNICOS DA RESIDENCIA DE CLÍNICA MÉDICA. **2017**, 4, 3
- 1612 Treatment target of diabetes for prevention of coronary artery disease. **2017**, 23, 170-173
- 1611 Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus. **2017**, 9, 2124-2134 19
- 1610 Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance. **2018**, 2, 53-62 4
- 1609 Diabetes. **2018**, 119-136
- 1608 The Antidiabetic Armamentarium: Reducing the Residual Cardiovascular Risk with HbA-Lowering Medications : Editorial to: "GLP-1 Receptor Agonists and Cardiovascular Disease: A Meta-Analysis of Recent Cardiac Outcome Trials" by Jia X, Alam M, Ye Y et al. **2018**, 32, 1-3
- 1607 L'efficacité thérapeutique : une préoccupation importante. L'exemple des biphosphates injectables dans le diabète de type 2. **2018**, 12, 36-45 2
- 1606 Treatment of type 2 diabetes mellitus in elderly patients. **2018**, 218, 74-88 3
- 1605 Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?. **2018**, 36, 138-147 5
- 1604 RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. **2018**, 38, 1-115 57
- 1603 Cardiometabolic Effects of Anti-obesity Pharmacotherapy. **2018**, 20, 18 5
- 1602 Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review. **2018**, 21, 881-890 93
- 1601 Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. **2018**, 6, 370-381 137
- 1600 Basic Concepts in Insulin Resistance and Diabetes Treatment. **2018**, 19-35 3
- 1599 2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. **2018**, 81, 189-222 14
- 1598 What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?. **2018**, 31, 12-14
- 1597 Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population. **2018**, 9, 637-650 15

- 1596 [Type 2 Diabetes Diabetes in Older Adults: Example for Patient-Centered Drug Therapy]. **2018**, 143, 253-261 0
- 1595 Rpondeurs et non-rpondeurs aux antidiabtiques. Dans lâattente de la pharmacoghtique, savoir rvaluer leur efficacit, surtout en regard de leurs coEs. **2018**, 12, 5-7
- 1594 Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial. **2018**, 41, 1009-1016 97
- 1593 Contemporary Advances in Myocardial Metabolic Imaging and Their Impact on Clinical Care: a Focus on Positron Emission Tomography (PET). **2018**, 11, 1 1
- 1592 The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus. **2018**, 34, 1081-10874
- 1591 Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability. **2018**, 11, 411-424 6
- 1590 Real-world evaluation of the DESMOND type 2 diabetes education and self-management programme. **2018**, 35, 19-22a 8
- 1589 The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions. **2018**, 23, 303-323 27
- 1588 Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England. **2018**, 20, 1659-1669 6
- 1587 Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. **2018**, 20, 853-872 264
- 1586 Targeting Other Modifiable Risk Factors for the Prevention of Heart Failure: Diabetes, Smoking, Obesity, and Inactivity. **2018**, 12, 1
- 1585 Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. **2018**, 20, 888-895 65
- 1584 Market licensing of type 2 diabetes medicinal products based on patient-relevant hard outcomes: is there hope?. **2018**, 4, 4-5
- 1583 Update of pathophysiology and management of diabetic kidney disease. **2018**, 117, 662-675 158
- 1582 Identification des rpondeurs au traitement par exhatide ou liraglutide : rsultats de deux tudes en vie relle. **2018**, 12, 62-68
- 1581 Do sulphonylureas still have a place in clinical practice?. **2018**, 6, 821-832 61
- 1580 Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management. **2018**, 34, 632-643 41
- 1579 Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes. **2018**, 139, 253-261 29

1578	Pharmacogenetics and target identification in diabetes. 2018 , 50, 68-73	8
1577	Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view. 2018 , 150, 275-281	1
1576	Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions. 2018 , 137, 1060-1073	20
1575	Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. 2018 , 130, 381-393	17
1574	Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?. 2018 , 32, 213-222	32
1573	Metabolic Karma-The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture. 2018 , 67, 785-790	15
1572	The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). 2018 , 17, 219-229	31
1571	Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology. 2018 , 142, 683-687.e12	27
1570	Clinical assessment and treatment of diabetes in patients with chronic kidney disease. 2018 , 218, 305-315	1
1569	Current understanding of the structure and function of family B GPCRs to design novel drugs. 2018 , 17, 45-59	19
1568	Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LiFEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors. 2018 , 8, 24	9
1567	Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus. 2018 , 11, 2-14	4
1566	Molecular and clinical roles of incretin-based drugs in patients with heart failure. 2018 , 23, 363-376	1
1565	Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes. 2018 , 18, 28	8
1564	Treatment of Diabetes in People With Heart Failure. 2018 , 42 Suppl 1, S196-S200	17
1563	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. 2018 , 42 Suppl 1, S88-S103	108
1562	ONE-YEAR TIME ANALYSIS IN AN ACADEMIC DIABETES CLINIC: QUANTIFYING OUR BURDEN. 2018 , 24, 489-491	5
1561	Diabetes in Older People. 2018 , 42 Suppl 1, S283-S295	45

1560	Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. 2018 , 319, 1580-1591	216
1559	The 2018 update of the American College of Physicians glycaemic management recommendations: An invitation to continued inertia?. 2018 , 20, 1809-1811	3
1558	Medically Supervised Weight Loss Programs. 2018 , 211-223	
1557	Agonistes du r�cepteur du GLP-1 : puissance ou transcendance ? Des outils pour contr�ler glyc�mie et pression art�rielle. 2018 , 12, 31-35	0
1556	Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes. 2018 , 34, 1457-1464	17
1555	The role of pollutants in type 2 diabetes mellitus (T2DM) and their prospective impact on phytomedicinal treatment strategies. 2018 , 190, 262	5
1554	Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. 2018 , 27, 740-756	441
1553	Sodium-Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus: A Review of Large-Scale Cardiovascular Outcome Studies and Possible Mechanisms of Benefit. 2018 , 26, 312-320	4
1552	Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure. 2018 , 20, 973-977	21
1551	Influence of Diabetes on Trends in Perioperative Cardiovascular Events. 2018 , 41, 1268-1274	20
1550	Treatment with GLP-1 Receptor Agonists. 2018 , 1-45	3
1549	Post-transplantation diabetes in kidney transplant recipients: an update on management and prevention. 2018 , 55, 763-779	30
1548	Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk. 2018 , 9, 919-926	23
1547	[Cardioprotection and diabetes mellitus - which antidiabetic agents seem to do better]. 2018 , 160, 65-70	
1546	Glucose-lowering treatment in cardiovascular and peripheral artery disease. 2018 , 39, 86-98	4
1545	Drug repurposing in kidney disease. 2018 , 94, 40-48	28
1544	Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure. 2018 , 35, 707-713	3
1543	Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity. 2018 , 137, 1614-1631	105

1542	Cardiovascular Protection in People With Diabetes. 2018 , 42 Suppl 1, S162-S169	30
1541	Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment. 2018 , 36, 1427-1440	48
1540	GLP-1 receptor agonist liraglutide exerts central action to induce β cell proliferation through medulla to vagal pathway in mice. 2018 , 499, 618-625	5
1539	Chronic Kidney Disease in Diabetes. 2018 , 42 Suppl 1, S201-S209	36
1538	The Vasculature in Prediabetes. 2018 , 122, 1135-1150	56
1537	Letter to the Editor: "GLP-1 Receptor Expression Within the Human Heart". 2018 , 159, 1964-1965	1
1536	CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. 2018 , 14, 361-377	203
1535	Legacy Effect of Intensive Blood Glucose Control on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Very High Risk or Secondary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized Controlled Trials. 2018 , 40, 776-788.e3	9
1534	Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?. 2018 , 10, 26	20
1533	GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials. 2018 , 32, 65-72	19
1532	MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. 2018 , 178, R127-R139	33
1531	Type 2 Diabetes and the Reduction of Cardiovascular Risk: Sorting Out the Actors and the Roles. 2018 , 34, 532-535	1
1530	Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns. 2018 , 29, 238-248	41
1529	Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population. 2018 , 183, 45-50	2
1528	Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. 2018 , 29, 95-103	15
1527	Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration. 2018 , 20, 1461-1469	10
1526	Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System. 2018 , 6, e000475	15
1525	Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?. 2018 , 14, 371-377	9

1524	Designing Medical, Point of Care Sensors to Aid Health Care Providers in Diagnosing and Managing Diseases: Addressing Pertinent Issues and Some Contemporary Opportunities. 2018 , 30, 310-313	
1523	Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes. 2018 , 9, 551-564	5
1522	Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study. 2018 , 12, 346-355	4
1521	Once-weekly GLP-1R agonists: moving the goal posts. 2018 , 6, 260-261	2
1520	Pathophysiological Links Between Diabetes and Blood Pressure. 2018 , 34, 585-594	24
1519	The Genetic Link Between Diabetes and Atherosclerosis. 2018 , 34, 565-574	7
1518	Obesity and hypertension in Latin America: Current perspectives. 2018 , 35, 70-76	14
1517	Treatment of type 2 diabetes mellitus in elderly patients. 2018 , 218, 74-88	22
1516	Glucose-lowering therapies in type 2 diabetes: Opportunities and challenges for peptides. 2018 , 100, 9-17	14
1515	Safety and tolerability of new-generation anti-obesity medications: a narrative review. 2018 , 130, 173-182	64
1514	Gut hormone polyagonists for the treatment of type 2 diabetes. 2018 , 100, 190-201	70
1513	Clinical features and therapeutic perspectives on hypertension in diabetics. 2018 , 41, 213-229	11
1512	Metabolic Surgery: Weight Loss, Diabetes, and Beyond. 2018 , 71, 670-687	75
1511	Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study. 2018 , 9, 583-612	173
1510	Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism. 2018 , 100, 94-100	11
1509	[Treatment of type 2 diabetes mellitus in elderly patients]. 2018 , 53, 89-99	8
1508	Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes. 2018 , 18, 343-351	7
1507	Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. 2018 , 122, 624-638	613

1506	Diabetes medications and cardiovascular disease: at long last progress. 2018 , 25, 87-93	9
1505	Pharmacotherapy for obesity in individuals with type 2 diabetes. 2018 , 19, 223-231	12
1504	Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin. 2018 , 20, 1367-1368	2
1503	Perspectives on diabetes mortality as the result of residual confounding and reverse causality by common disease. 2018 , 20, 1342-1349	3
1502	Updates on obesity pharmacotherapy. 2018 , 1411, 106-119	38
1501	Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors. 2018 , 23, 377-388	11
1500	Incremental burden of type 2 diabetes in patients experiencing cardiovascular hospitalizations. 2018 , 34, 1005-1012	
1499	A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. 2018 , 17, 293-302	22
1498	Hypertension and Diabetes Mellitus: Coprediction and Time Trajectories. 2018 , 71, 422-428	76
1497	Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities. 2018 , 319, 291-301	166
1496	[Prevention of cardiovascular diseases]. 2018 , 43, 87-100	1
1495	Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. 2018 , 61, 1503-1516	40
1494	Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke. 2018 , 39, 2376-2386	38
1493	Neuroprotective Mechanisms of Glucagon-like Peptide-1-based Therapies in Ischaemic Stroke: A Systematic Review based on Pre-Clinical Studies. 2018 , 122, 559-569	25
1492	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus. 2018 , 47, 81-96	30
1491	Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease. 2018 , 47, 137-152	6
1490	The Evolving Epidemiology of Atherosclerotic Cardiovascular Disease in People with Diabetes. 2018 , 47, 1-32	12
1489	Oxyntomodulin: Actions and role in diabetes. 2018 , 100, 48-53	40

1488	Newer GLP-1 receptor agonists and obesity-diabetes. 2018 , 100, 61-67	29
1487	Diabetes and ischaemic stroke: a deadly association. 2018 , 39, 2387-2389	3
1486	Trends in Diabetes Treatment and Monitoring among Medicare Beneficiaries. 2018 , 33, 471-480	12
1485	All Inkjet-Printed Amperometric Multiplexed Biosensors Based on Nanostructured Conductive Hydrogel Electrodes. 2018 , 18, 3322-3327	133
1484	Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio. 2018 , 52, 632-638	6
1483	Associations between body mass index and the risk of renal events in patients with type 2 diabetes. 2018 , 8, 7	19
1482	The pharmacological management of metabolic syndrome. 2018 , 11, 397-410	56
1481	Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials. 2018 , 20, 1235-1245	19
1480	Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential. 2018 , 9, 33-50	26
1479	Hypertension with diabetes mellitus complications. 2018 , 41, 147-156	43
1478	Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis. 2018 , 7,	66
1477	Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes. 2018 , 130, 154-158	5
1476	Ranting in 2018: Are We Making Progress?. 2018 , 20, 91-93	
1475	Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect. 2018 , 41, 219-223	11
1474	No Impact of Pre-existing Cardiovascular Disease on Prescribing Patterns of Sulphonylureas in Denmark - A Registry-based Nationwide Study. 2018 , 122, 606-611	1
1473	Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. 2018 , 20, 1361-1366	52
1472	Clinical impact of oral antidiabetic medications in heart failure patients. 2018 , 23, 325-335	7
1471	Effect of glucose-lowering therapies on heart failure. 2018 , 15, 282-291	34

1470	Incretins: Beyond type 2 diabetes. 2018 , 20 Suppl 1, 59-67	6
1469	A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. 2018 , 20 Suppl 1, 22-33	118
1468	What have we learnt from "real world" data, observational studies and meta-analyses. 2018 , 20 Suppl 1, 47-58	32
1467	Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis. 2018 , 20, 1262-1279	24
1466	Comment on Han et al. Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans. <i>Diabetes Care</i> 2017;40:218-225. 2018 , 41, e6	
1465	The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. 2018 , 23, 445-459	4
1464	The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial. 2018 , 22, 825-834	4
1463	Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs. 2018 , 254, 291-296	23
1462	No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. 2018 , 41, 620-622	21
1461	Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial. 2018 , 41, 604-612	35
1460	Heart Failure: Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus. 2018 , 47, 117-135	16
1459	Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view. 2018 , 150, 275-281	4
1458	Management of diabetes in older adults. 2018 , 28, 206-218	30
1457	American Heart Association 2017. 2018 , 10, 271-275	1
1456	Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trial. 2018 , 9, 840-849	5
1455	New Therapies in Obesity. 2018 , 271-279	0
1454	Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study. 2018 , 35, 243-253	12
1453	Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes. 2018 , 29, 246-253	12

1452	Novel therapies for diabetic kidney disease. 2018 , 8, 18-25	23
1451	A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure. 2018 , 104, 546-552	16
1450	Silent Myocardial Infarction: Listen to the Evidence. 2018 , 71, 9-11	5
1449	Obesity: Pathophysiology and Management. 2018 , 71, 69-84	192
1448	Type 2 diabetes: glycaemic control. 2018 , 241-313	
1447	Albiglutide for the management of type 2 diabetes. 2018 , 13, 1-8	6
1446	Diabetes and chronic kidney disease: an increasingly common multi-morbid disease in need of a paradigm shift in care. 2018 , 35, 300-305	55
1445	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors' Expert Forum. 2018 , 41, 14-31	263
1444	GLP-1 receptor agonists: differentiation within the class. 2018 , 6, 83-85	23
1443	GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose. 2018 , 9, 113	78
1442	Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. 2018 , 154, 1309-1319.e7	39
1441	Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized clinical trials. 2018 , 20, 1213-1222	25
1440	Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. 2018 , 23, 419-437	53
1439	Age affects the prognostic impact of diabetes in chronic heart failure. 2018 , 55, 271-278	5
1438	GLP-1 receptor agonists and cardiovascular protection: A class effect or not?. 2018 , 44, 193-196	15
1437	Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?. 2018 , 24, 109-111	2
1436	Epigenetic Contribution to the Development and Progression of Vascular Diabetic Complications. 2018 , 29, 1074-1091	6
1435	Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?. 2018 , 131, 461-463	4

1434	Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page. 2018 , 137, 130-133	7
1433	Have we really demonstrated the cardiovascular safety of anti-hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes. 2018 , 20, 1089-1095	4
1432	Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition. 2018 , 282, 13-21	10
1431	Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. 2018 , 20, 1515-1519	28
1430	Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment. 2018 , 23, 469-479	4
1429	From the editor: A run of success in treating atherosclerotic vascular disease. 2018 , 12, 1-2	
1428	Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials. 2018 , 8, 8-17	6
1427	Cardioprotective anti-hyperglycaemic medications: a review of clinical trials. 2018 , 39, 2368-2375	26
1426	Canagliflozin and cardiovascular and renal events in type 2 diabetes. 2018 , 130, 149-153	21
1425	Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS. 2018 , 7, 115-123	10
1424	Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus. 2018 , 16, 123-131	
1423	Managing diabetic kidney disease. 2018 , 125, 55-66	7
1422	The year in cardiology 2017: prevention. 2018 , 39, 345-353	3
1421	Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents. 2018 , 78, 203-214	5
1420	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. 2018 , 6, 105-113	336
1419	Association of Diabetic Status and Glycemic Control With Ischemic and Bleeding Outcomes in Patients With Stable Coronary Artery Disease: The 5-Year CORONOR Registry. 2018 , 7,	4
1418	Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review. 2018 , 19, 36	27
1417	The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors. 2018 , 17, 32	13

1416	Cardiovascular magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control and clinical outcomes. 2018 , 17, 35	10
1415	Rationale, design, and baseline characteristics of the Cardiovascular safety and Renal Microvascular outcomE study with LINagliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. 2018 , 17, 39	57
1414	Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy. 2018 , 17, 52	33
1413	Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. 2018 , 17, 54	17
1412	Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial. 2018 , 10, 30	15
1411	The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data. 2018 , 17, 83-95	2
1410	Summary of the 2018 ISN Frontiers Meeting: Kidney Disease and Cardiovascular Disease. 2018 , 3, 804-816	78
1409	Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. 2018 , 94, 26-39	160
1408	Comparison of the Effects of Teneigliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus. 2018 , 40, 1-9	2
1407	Normoglucemiantes orales y riesgo cardiovascular. 2018 , 25, 333-339	
1406	Glucagon-like peptide 1 in health and disease. 2018 , 14, 390-403	187
1405	Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials. 2018 , 20, 2131-2139	9
1404	SGLT2 inhibition and heart failure-current concepts. 2018 , 23, 409-418	21
1403	Precision medicine in the management of type 2 diabetes. 2018 , 6, 891-900	60
1402	A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes. 2018 , 20, 2064-2074	
1401	Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. 2018 , 15, 425-439	114
1400	Unexplained reciprocal regulation of diabetes and lipoproteins. 2018 , 29, 186-193	11
1399	Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial. 2018 , 20, 2121-2130	17

1398	New antihyperglycaemic agents and cardiovascular disease: let's be optimistic. 2018 , 33, 444-454	3
1397	Management of Diabetes and/or Hyperglycemia in Hospitalized Patients with Renal Insufficiency. 2018 , 598-615	1
1396	Management of Diabetes and/or Hyperglycemia in Acute Coronary Syndrome, Acute Stroke, and Acute Heart Failure. 2018 , 632-647	
1395	Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials. 2018 , 27, 1301-1309	2
1394	Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. 2018 , 202, 39-48	12
1393	Diabetes and the Kidney: Sweet Dreams. 2018 , 25, 115-118	1
1392	Pharmacotherapeutic strategies for treating hypertension in patients with obesity. 2018 , 19, 643-651	8
1391	Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol. 2018 , 9, 1397-1402	3
1390	HbA1C, finding the right target in 2018. 2018 , 12, 607-608	1
1389	Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications. 2018 , 6, 445-451	42
1388	Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Nephilysin, and Sodium-Glucose Cotransporter-2. 2018 , 6, 633-639	80
1387	New pharmacological approaches for cardiovascular risk. 2018 , 151, 145-147	
1386	Diabetes and Hypertension: Clinical Update. 2018 , 31, 515-521	9
1385	GLP-1 Receptor Expression Within the Human Heart. 2018 , 159, 1570-1584	100
1384	Potential mechanisms underlying differences in the effect of incretin-based antidiabetic drugs on the risk of major atherosclerotic ischemic events. 2018 , 32, 616-617	
1383	Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review. 2018 , 9, 877-890	27
1382	Preventing the development and progression of diabetic kidney disease: Where do we stand?. 2018 , 12, 585-590	4
1381	New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. 2018 , 18, 27	36

1380	The Science of Obesity Management: An Endocrine Society Scientific Statement. 2018 , 39, 79-132	304
1379	Dyspnoe bei Diabetes und Herzinsuffizienz. 2018 , 14, 36-43	1
1378	Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). 2018 , 121, 1467-1470	17
1377	Diabetestherapie bei Niereninsuffizienz. 2018 , 14, 86-92	
1376	Renal Hyperfiltration in Adolescents with Type 2 Diabetes: Physiology, Sex Differences, and Implications for Diabetic Kidney Disease. 2018 , 18, 22	21
1375	WITHDRAWN: Nonalcoholic steatohepatitis therapies. 2018 ,	
1374	Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies. 2018 , 29, 246-258	5
1373	The Versatile Tanycyte: A Hypothalamic Integrator of Reproduction and Energy Metabolism. 2018 , 39, 333-368	115
1372	Liraglutide attenuates NLRP3 inflammasome-dependent pyroptosis via regulating SIRT1/NOX4/ROS pathway in H9c2 cells. 2018 , 499, 267-272	54
1371	Moving Beyond the Stent: Identifying the Percutaneous Coronary Intervention Patient With Silent Diabetes and Pre-Diabetes. 2018 , 11, 460-461	1
1370	Glycemic Control as Primary Prevention for Diabetic Kidney Disease. 2018 , 25, 141-148	9
1369	New Glucose-Lowering Agents for Diabetic Kidney Disease. 2018 , 25, 149-157	10
1368	Decrease mortality in type II diabetes mellitus: glycemic and renal function control. 2018 , 19 Suppl 1, e13-e15	
1367	Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. 2018 , 272, 33-40	24
1366	European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRs) and Latin American Heart Rhythm Society (LAHRS). 2018 , 20, 895-896	13
1365	JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. 2018 , 33, 1950-1959	118
1364	Perspectives of Patients with Insulin-Treated Type 1 and Type 2 Diabetes on Hypoglycemia: Results of the HAT Observational Study in Central and Eastern European Countries. 2018 , 9, 727-741	4
1363	Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting. 2018 , 55, 557-568	14

1362	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. 2018 , 71, 1379-1390	43
1361	The controversy of social media at conferences. 2018 , 121, 823-824	3
1360	Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus. 2018 , 43, 68-110	15
1359	Medication use for the treatment of diabetes in obese individuals. 2018 , 61, 265-272	25
1358	Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions. 2018 , 20, 238-244	42
1357	Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies. 2018 , 10, 94-111	12
1356	No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer. 2018 , 35, 381-385	4
1355	Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes. 2018 , 20, 178-184	16
1354	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. 2018 , 33, 86-98	71
1353	Diabetic Kidney Disease. 2018 , 13, 335-338	16
1352	SGLT2 inhibitors: are they safe?. 2018 , 130, 72-82	36
1351	Effects of incretin-based therapies on renal function. 2018 , 818, 103-109	10
1350	High overall cardiovascular risk and mortality in patients with atrial fibrillation and diabetes: A nationwide report. 2018 , 15, 31-38	15
1349	Pharmacotherapy for Patients with Obesity. 2018 , 64, 118-129	29
1348	Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?. 2018 , 20, 627-629	9
1347	Novel Biomarkers for Predicting Cardiovascular Disease in Patients With Diabetes. 2018 , 34, 624-631	8
1346	Safety of diabetes drugs in patients with heart failure. 2018 , 218, 98-107	
1345	Prevalence of micro- and macrovascular diabetes complications at time of type 2 diabetes diagnosis and associated clinical characteristics: A cross-sectional baseline study of 6958 patients in the Danish DD2 cohort. 2018 , 32, 34-40	53

1344	Marked exercise-induced T-wave heterogeneity in symptomatic diabetic patients with nonflow-limiting coronary artery stenosis. 2018 , 23, e12503	5
1343	Role of structured individual patient education in the prevention of vascular complications in newly diagnosed type 2 diabetes: the Individual Therapeutic Education in Newly Diagnosed type 2 diabetes (INTEND) randomized controlled trial. 2018 , 60, 46-49	10
1342	Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial. 2018 , 6, 8-17	96
1341	Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons. 2018 , 20, 508-519	25
1340	Commissioning guidance for weight assessment and management in adults and children with severe complex obesity. 2018 , 19, 14-27	23
1339	Postmeal increment in intact glucagon-like peptide 1 level, but not intact glucose-dependent insulinotropic polypeptide levels, is inversely associated with metabolic syndrome in patients with type 2 diabetes. 2018 , 43, 47-54	3
1338	Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study. 2018 , 196, 18-27	13
1337	Gender-Related Differences in the Control of Cardiovascular Risk Factors in Primary Care for Elderly Patients With Type 2 Diabetes: A Cohort Study. 2018 , 42, 365-371.e2	3
1336	The kidney and cardiovascular outcome trials. 2018 , 10, 88-89	27
1335	Effect of glycemic control on the Diabetes Complications Severity Index score and development of complications in people with newly diagnosed type 2 diabetes. 2018 , 10, 192-199	23
1334	Heart failure with preserved ejection fraction: current management and future strategies : Expert opinion on the behalf of the Nucleus of the "Heart Failure Working Group" of the German Society of Cardiology (DKG). 2018 , 107, 1-19	57
1333	Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. 2018 , 20, 734-739	42
1332	Antidiabetic drugs and stroke risk. Current evidence. 2018 , 48, 1-5	20
1331	Safety of diabetes drugs in patients with heart failure. 2018 , 218, 98-107	
1330	Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure. 2018 , 23, 481-497	2
1329	Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients. 2018 , 9, 360-365	9
1328	Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. 2018 , 20, 497-507	22
1327	Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy. 2018 , 34, 1-10	9

1326	Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential. 2018 , 136, 280-286	27
1325	Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option. 2018 , 66, 7-10	36
1324	European Society of Cardiology 2017. 2018 , 10, 6-9	
1323	Progress and challenges in anti-obesity pharmacotherapy. 2018 , 6, 237-248	118
1322	Pharmacotherapy of type 2 diabetes: An update. 2018 , 78, 13-42	103
1321	Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes. 2018 , 52, 78-85	4
1320	Type 2 diabetes and cardiovascular prevention: the dogmas disputed. 2018 , 60, 224-228	8
1319	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. 2018 , 20, 889-897	114
1318	Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. 2018 , 41, 348-355	10
1317	Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes. 2018 , 44, 4-14	51
1316	Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. 2018 , 20, 910-920	14
1315	10. Microvascular Complications and Foot Care:. 2018 , 41, S105-S118	205
1314	Efficacy and safety of sotagliflozin in treating diabetes type 1. 2018 , 19, 307-315	5
1313	Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. 2018 , 34, 575-584	435
1312	Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes. 2018 , 20, 800-811	5
1311	The Glucagon-Like Peptide-1 Analog Exenatide Increases Blood Glucose Clearance, Lactate Clearance, and Heart Rate in Comatose Patients After Out-of-Hospital Cardiac Arrest. 2018 , 46, e118-e125	5
1310	Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. 2018 , 41, 577-585	16
1309	Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes. 2018 , 47, 97-116	2

1308	SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus. 2018 , 136, 23-31	13
1307	Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. 2018 , 20, 974-984	46
1306	9. Cardiovascular Disease and Risk Management:. 2018 , 41, S86-S104	370
1305	Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins. 2018 , 12, 62-69.e1	9
1304	Cardiovascular Complications Over 5 Years and Their Association With Survival in the GERODIAB Cohort of Elderly French Patients With Type 2 Diabetes. 2018 , 41, 156-162	15
1303	Diabetes area patent participation analysis - part II: years 2011-2016. 2018 , 28, 111-122	5
1302	Targeting postprandial glycaemia in children with diabetes: Opportunities and challenges. 2018 , 20, 766-774	2
1301	Novel avenues for drug discovery in diabetic kidney disease. 2018 , 13, 65-74	7
1300	10th Annual Symposium on Self-Monitoring of Blood Glucose, April 27-29, 2017, Warsaw, Poland. 2018 , 20, 68-89	4
1299	Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study. 2018 , 9, 363-371	3
1298	Diabetes Canada 2017. 2018 , 10, 188-191	
1297	Metabolic Effects of Bariatric Surgery. 2018 , 64, 72-81	16
1296	Development and characterisation of a novel glucagon like peptide-1 receptor antibody. 2018 , 61, 711-721	15
1295	Canagliflozin: Cui Bono?. 2018 , 137, 335-337	3
1294	Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). 2018 , 137, 323-334	284
1293	Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus. 2018 , 9, 27-36	5
1292	Renal outcomes with dipeptidyl peptidase-4 inhibitors. 2018 , 44, 101-111	18
1291	Oral Antidiabetic Agents and Cardiovascular Outcomes. 2018 , 43, 111-126	4

1290	Pharmaceutical Interventions for Diabetes Prevention in Patients at Risk. 2018 , 18, 13-24	2
1289	Prospective study of metabolic syndrome as a mortality marker in chronic coronary heart disease patients. 2018 , 47, 55-61	7
1288	Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New. 2018 , 42, 325-334	10
1287	The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes. 2018 , 52, 69-77	8
1286	Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist). 2018 , 7, 32	
1285	L'Internista ospedaliero nella gestione del paziente diabetico complesso. 2018 , 6, 1	0
1284	Pharmacological Intervention for the Prevention of Diabetes Mellitus. 2018 , 19, 140	
1283	Impact of a multifactorial treatment programme on clinical outcomes and cardiovascular risk estimates: a retrospective cohort study from a specialised diabetes centre in Denmark. 2018 , 8, e019214	10
1282	Tackling Cardiovascular Risk in Type 2 Diabetes: Does Baseline Glucose Control Matter?. 2018 , 4-5, 6-7	
1281	Is there an association between liraglutide use and female breast cancer in a real-world setting?. 2018 , 11, 791-806	8
1280	Moderne Antidiabetika in der Diabetologie. 2018 , 7, 292-300	
1279	Regional differences in the incidence of diabetic cardiovascular events reflect the quality of care. 2018 , 52, 232-237	2
1278	Echocardiographic feature of diabetic cardiomyopathy: where are we now?. 2018 , 8, 47-56	18
1277	The ABCs of chronic kidney disease. 2018 , 31, 17-25	2
1276	Klinische Stadieneinteilung der diabetischen Retinopathie. 2018 , 14, 550-556	1
1275	Short-Term Outcomes for Veterans Receiving Basal Insulin, Metformin, and a Sulfonylurea Who Are Started on a Third Noninsulin Agent Versus Prandial Insulin. 2018 , 31, 261-266	1
1274	Life-style-induced metabolic derangement and epigenetic changes promote diabetes and oxidative stress leading to NASH and atherosclerosis severity. 2018 , 17, 381-391	9
1273	S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter. 2018 , 13, 423-489	9

1272	TNM cancer staging: can it help develop a novel staging system for type 2 diabetes?. 2018 , 11, 845-853	1
1271	Evaluating the Diabetes-Cardiology interface: a glimpse into the diabetes management of cardiology inpatients in western Sydney's 'diabetes hotspot' and the establishment of a novel model of care. 2018 , 10, 90	3
1270	Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018. 2018 , 168, 640-650	48
1269	Cardioprotective glucose-lowering medications: evidence and uncertainties in a new therapeutic era. 2018 , 7, 2-3	4
1268	Moderne Antidiabetika in der Kardiologie. 2018 , 7, 286-291	1
1267	Therapie des Typ-2-Diabetes. 2018 , 13, S144-S165	7
1266	Aggravation précoce de la rétinopathie diabétique lors de l'optimisation du contrôle glycémique. 2018 , 12, 560-570	1
1265	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. 2018 , 9, CD011798	27
1264	Glucagon-like peptide (GLP)-1 analogues as an add-on to insulin for adults with type 1 diabetes mellitus. 2018 ,	78
1263	SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists. 2018 , 10, 615-625	9
1262	Paradigm Changes in Diabetes Management Guidelines: American Diabetes Association 2018. 2018 , 19, 71	0
1261	Update on renal disease in diabetic patients in primary care. 2018 , 2018, 32-36	
1260	Cardiovascular outcome trials in diabetes: what have we learnt?. 2018 , 9, 7-12	
1259	Bei Herzpatienten haben GLP-1-Agonisten Vorfahrt vor Insulin. 2018 , 12, 50-50	
1258	Das Herz ist Achillesferse bei Typ-2-Diabetes. 2018 , 12, 54-54	1
1257	OBSOLETE: Hormonal Therapy for Heart Failure. 2018 ,	
1256	Full Issue PDF. 2018 , 3, I-CLVIII	
1255	Treatment approach to type 2 diabetes: Past, present and future. 2018 , 9, 209-219	32

1254 Archaeology. **2018**, 74, 95-156

1253 Inhibiteurs des SGLT2 : lâffet classe se confirme. **2018**, 12, 637-639

1252 Diabetes Typ 2: Sulfonylharnstoffe erhâen kardiovaskulâes Risiko. **2018**, 143, 1515-1518

1251 The mode and mechanism of action of once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes. **2018**, 30, S12-S18 0

1250 Cardiovascular outcome trials in type 2 diabetes: A nurse practitioner perspective. **2018**, 30, S43-S52 0

1249 Diabetes mellitus und Herz. **2018**, 13, S214-S216

1248 7. Fallstricke in der pharmakologischen Therapie des Diabetes. **2018**, 128-140

1247 Herzinsuffizienz und Diabetes. **2018**, 16, 148-155

1246 Overview of the burden of illness and the role of once-weekly glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes. **2018**, 30, S4-S11 0

1245 . **2018**, 1

1244 The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes. **2018**, 18, 144 4

1243 Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes: a pathophysiology-based review of clinical implications. **2018**, 33, 665-675 5

1242 Systematic review of incretin therapy during peri-operative and intensive care. **2018**, 22, 299 14

1241 Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. **2018**, 9, 672 96

1240 Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update. **2018**, 65, 611-624

1239 Diabetestherapie mit oralen Antidiabetika bei chronischer Niereninsuffizienz. **2018**, 13, 425-434

1238 Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. **2018**, 53, 1429-1432 9

1237 The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. **2018**, 14, 1287-1302 41

1236	2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. 2018 , 72, 3200-3223	180
1235	Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective. 2018 , 10, 791-803	9
1234	Incretin-based therapy for diabetic ulcers: from bench to bedside. 2018 , 27, 989-996	2
1233	The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE and LDLr Mice by a Mechanism That Includes Inflammatory Pathways. 2018 , 3, 844-857	108
1232	Type-2 diabetes mellitus and cardiovascular disease. 2018 , 14, 491-509	87
1231	Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial. 2018 , 41, 2603-2609	16
1230	Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. 2018 , 72, 2297-2305	24
1229	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol. 2018 , 8, e023206	4
1228	Lessons Learned From Multi-regional Trials With Signals of Treatment Effect Heterogeneity. 2018 , 216847901880542	
1227	Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. 2018 , 10,	192
1226	Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. 2018 , 363, k4365	159
1225	Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes. 2018 , 2018, 3106056	40
1224	[Diabetology: The most important innovations of the past 10 years]. 2018 , 160, 38-42	
1223	Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. 2018 , 9, 1514	80
1222	Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review. 2018 , 93, 1629-1647	20
1221	Different mechanisms involved in liraglutide and glucagon-like peptide-1 vasodilatation in rat mesenteric small arteries. 2019 , 176, 386-399	9
1220	Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs. 2018 , 21, 80-86	2
1219	[Use of dipeptidyl peptidase-4 inhibitors in patients with diabetes]. 2018 , 44 Suppl 1, 10-17	

- 1218 [Use of dipeptidyl peptidase-4 inhibitors in diabetic patients in special situations]. **2018**, 44 Suppl 1, 18-25
- 1217 Fármacos que mejoran el pronóstico cardiovascular en diabetes y los cardiólogos aún no usamos. **2018**, 71, 999-1000 3
- 1216 Introduction. **2018**, 24, S3-S4
- 1215 Consensus document of the Spanish Society of Arteriosclerosis (SEA) for the prevention and treatment of cardiovascular disease in type 2 diabetes mellitus. **2018**, 30 Suppl 1, 1-19 2
- 1214 Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update. **2018**, 65, 611-624 19
- 1213 Cardiovascular Benefits of GLP-1 Receptor Agonism: Is Inflammation a Key?. **2018**, 3, 858-860 5
- 1212 Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis. **2018**, 2018, 1232583 48
- 1211 Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. **2018**, 70, 915-921 3
- 1210 More cardiovascular outcomes trials in people with diabetes: time to change the NICE guidelines. **2018**, 35, 193-194
- 1209 Updates in heart failure: what last year brought to us. **2018**, 5, 989-1007 6
- 1208 The Intersection of Diabetes and Cardiovascular Disease-A Focus on New Therapies. **2018**, 5, 160 4
- 1207 Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease. **2018**, 138, 2576-2578 9
- 1206 Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. **2018**, 1, e186125 45
- 1205 GLP-1 Is a Coronary Artery Vasodilator in Humans. **2018**, 7, e010321 11
- 1204 GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. **2018**, 17, 157 60
- 1203 Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial. **2018**, 72, 3274-3284 31
- 1202 The Heart and Vascular Team: Time for Endocrinologists to Join the Club?. **2018**, 72, 3285-3286
- 1201 Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss. **2018**, 10, 14

1200	GLP1 Receptor Agonist Liraglutide Is an Effective Therapeutic Option for Perioperative Glycemic Control in Type 2 Diabetes within Enhanced Recovery After Surgery (ERAS) Protocols. 2018 , 59, 349-360	6
1199	Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment. 2018 , 8, 17545	11
1198	The past decade in type 2 diabetes and future challenges. 2018 , 17, 451-459	7
1197	Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. 2018 , 363, k4880	23
1196	Incretins and cancer of the bile duct in type 2 diabetes. 2018 , 363, k5155	0
1195	Clinical and Investigative Endocrinology and Diabetes. 2018 , 24 Suppl 2, 1-22	0
1194	Physical exercise and non-insulin glucose-lowering therapies in the management of Type 2 diabetes mellitus: a clinical review. 2019 , 36, 349-358	8
1193	Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). 2018 , 17, 150	73
1192	Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?. 2018 , 28, 813-815	16
1191	By What Standard Should We Manage Diabetes?. 2018 , 36, 12-13	1
1190	The future of febuxostat after the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial: who CARES?. 2018 , 19, 1853-1856	6
1189	Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. 2018 , 25, 315-320	5
1188	Obesity and nonalcoholic fatty liver disease: current perspectives. 2018 , 11, 533-542	85
1187	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. 2018 , 39, 4243-4254	113
1186	Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes. 2018 , 39, 719-738	75
1185	Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications. 2018 , 20, 112	4
1184	Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?. 2018 , 20, 113	16
1183	[Therapy algorithm in type 2 diabetes]. 2018 , 160, 48-56	

1182	Medication-based versus target-based lipid management. 2018 , 10, 789-792	0
1181	Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study. 2018 , 9, 2201-2208	7
1180	Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy. 2018 , 25, 327-341	12
1179	Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?. 2018 , 19, 1655-1661	5
1178	2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. 2018 , 36, 1953-2041	1262
1177	Reaching an ACCORD on Glycemia and Systolic Blood Pressure Targets in Type 2 Diabetes Mellitus. 2018 , 7, e010508	1
1176	Cardiovascular Safety of Antihyperglycemic Agents: "Do Good or Do No Harm". 2018 , 78, 1567-1592	1
1175	Glucagon secretion determined by the RIA method is lower in patients with low left ventricular ejection fraction: The new glass study. 2018 , 144, 260-269	1
1174	The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review. 2018 , 72, 1856-1869	43
1173	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. 2018 , 392, 1519-1529	771
1172	HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?. 2018 , 392, 1489-1490	5
1171	Clinical management of type 2 diabetes in south Asia. 2018 , 6, 979-991	26
1170	Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. 2018 , 6, 859-869	122
1169	Endpunktstudien in der Diabetestherapie. 2018 , 14, 376-383	
1168	Glucose lowering and the kidney: are all drug classes equal?. 2018 , 6, 835-837	
1167	Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. 2018 , 138, 2908-2918	48
1166	Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus. 2018 , 7, e009379	22
1165	[The Beneficial Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Dulaglutide on Plasma Glucose and Hemoglobin A1c Levels: A Case Report of Four Patients with Type 2 Diabetes]. 2018 , 138, 1323-1327	1

1164	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 2018 , 61, 2461-2498	656
1163	Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. 2018 , 392, 2180-2193	319
1162	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. 2018 , 392, 2269-2279	46
1161	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 2018 , 41, 2669-2701	1307
1160	The Role of Deprescribing in Older Adults with Chronic Kidney Disease. 2018 , 35, 973-984	21
1159	Letter by Tampaki et al Regarding Article, "Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors". 2018 , 123, e1-e2	
1158	Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin. 2018 , 103, 3611-3619	18
1157	The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. 2018 , 38, 1089-1108	8
1156	Designing and Analyzing Recurrent Event Data Trials. 2018 , 115-147	
1155	Managing Chronic Coronary Artery Disease in Patients with Diabetes. 2018 , 355-373	
1154	Activated iRhom2 drives prolonged PM exposure-triggered renal injury in Nrf2-defective mice. 2018 , 12, 1045-1067	12
1153	Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. 2018 , 19, 1903-1914	10
1152	Semaglutide once-weekly: improved efficacy with a new safety warning. 2018 , 11, 1061-1072	7
1151	The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients. 2018 , 72, e13274	5
1150	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. 2018 , 190, E1192-E1206	16
1149	Maternal obesity and offspring risk of chronic kidney disease. 2018 , 23 Suppl 4, 84-87	8
1148	Chronic kidney disease epidemic: How do we deal with it?. 2018 , 23 Suppl 4, 116-120	42
1147	Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). 2018 , 137, 219-229	35

1146	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. 2018 , 138, 2884-2894	50
1145	Lower extremity arterial disease in patients with diabetes: a contemporary narrative review. 2018 , 17, 138	58
1144	Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetes. 2018 , 13, 333-339	5
1143	Kardiovaskuläre Erkrankungen bei Diabetes. 2018 , 14, 393-403	1
1142	Modulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1). 2018 , 11, e006740	14
1141	Design of Lipid-Protein Conjugates Using Amphiphilic Peptide Substrates of Microbial Transglutaminase.. 2018 , 1, 1823-1829	10
1140	Safety of once-weekly glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes. 2018 , 30, S29-S42	2
1139	Diabetes und Herz. 2018 , 14, 374-375	
1138	Liraglutide and Glycaemic Outcomes in the LEADER Trial. 2018 , 9, 2383-2392	13
1137	How to Interpret Recent CV Outcome Trials and Future: PCSK9 Inhibitors. 2018 , 7, 1	0
1136	Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association. 2018 , 19, 35	
1135	Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. 2018 , 1, e00036	18
1134	Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice. 2018 , 14, 40-49	9
1133	Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword. 2018 , 17, 134	69
1132	Evidence-Based Management of Diabetes in Older Adults. 2018 , 35, 1065-1078	11
1131	Diabetes and Atherosclerosis: Old Players in a New Field, Osteoporosis. 2018 , 16, 524-527	9
1130	Preventing Macrovascular Events With Bariatric Surgery. 2018 , 320, 1545-1547	3
1129	Incretin-based drugs and hospitalization for heart failure in the clinical practice: A nested case-control study. 2018 , 146, 172-179	2

1128	Treatment with GLP-1 Receptor Agonists. 2018 , 571-615	1
1127	Clinical inertia among patients with type 2 diabetes mellitus treated with DPP-4i and/or SGLT-2i. 2018 , 146, 162-171	1
1126	Clinical Practice Recommendations for the Management of Obesity in the United Arab Emirates. 2018 , 11, 413-428	6
1125	COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. 2018 , 11, 683-697	7
1124	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. 2018 , 25, 846-984	295
1123	Technology in Diabetes Treatment: Update and Future. 2018 , 42, 1017-1027	3
1122	Revisiting the Diabetes-Heart Failure Connection. 2018 , 18, 134	8
1121	The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea. An Official American Thoracic Society Clinical Practice Guideline. 2018 , 198, e70-e87	78
1120	Cardiology Consult Manual. 2018 ,	
1119	Routine use of HbA1c amongst inpatients hospitalised with decompensated heart failure and the association of dysglycaemia with outcomes. 2018 , 8, 13564	3
1118	Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort. 2018 , 137, 270-279	6
1117	Diabetes Treatment in the Elderly: Incorporating Geriatrics, Technology, and Functional Medicine. 2018 , 18, 95	12
1116	Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis. 2018 , 6, 823-830	28
1115	Diabetic nephropathy: newer therapeutic perspectives. 2018 , 8, 200-207	27
1114	World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification: Commentary From the American College of Physicians High Value Care Committee. 2018 , 169, 398-400	5
1113	Medikamentöse Therapie der diabetischen Retinopathie – Die diabetologische Perspektive. 2018 , 14, 568-576	3
1112	Effect of saxagliptin on the expression of HIF-1 α in the liver of diabetic rats with fatty liver. 2018 , 16, 2559-2563	3
1111	Biopharmaceutical Applied Statistics Symposium. 2018 ,	

1110	Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data. 2018 , 11, 187-197	14
1109	Primary and Secondary Prevention of Cardiovascular Disease. 2018 , 63-76	
1108	Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis. 2018 , 19, 58	10
1107	Spotlight on Antidiabetic Agents with Cardiovascular or Renoprotective Benefits. 2018 , 22, 18-034	1
1106	Age-Related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk. 2018 , 123, 886-904	90
1105	Drugs That Improve Cardiovascular Prognosis in Diabetes and Are Not Yet Used by Cardiologists. 2018 , 71, 999-1000	1
1104	Incretin drugs as modulators of atherosclerosis. 2018 , 278, 29-38	23
1103	2018 Standards of Care Update: Pharmacologic Approaches to Glycemic Management in People With Type 2 Diabetes. 2018 , 31, 254-260	3
1102	Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes. 2018 , 103, 3456-3465	5
1101	iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes. 2018 , 31, 145-154	15
1100	Design and baseline characteristics of the eValuation of ERTugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). 2018 , 206, 11-23	139
1099	Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications. 2018 , 24, S42-S52	5
1098	Semaglutide for the Treatment of Type 2 Diabetes Mellitus. 2018 , 34, 281-289	1
1097	Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer. 2018 , 15, 606-624	43
1096	Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function. 2018 , 15, 494-503	21
1095	Treatment of Diabetes in Patients with Heart Failure. 2018 , 20, 97	
1094	Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy. 2018 , 41, 2330-2338	18
1093	Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes. 2018 , 18, 92	18

1092	Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease. 2018 , 17, 117	4
1091	Antihyperglycemic Medications and Impact on Cardiovascular Outcomes: A Review of Current Evidence. 2018 , 38, 739-757	3
1090	Gestione terapeutica del diabete di tipo 2. 2018 , 20, 1-7	
1089	Sitagliptin on carotid intima-media thickness in type 2 diabetes patients receiving primary or secondary prevention of cardiovascular disease: A subgroup analysis of the PROLOGUE study. 2018 , 271, 331-335	7
1088	Glucose lowering strategies and cardiovascular disease in type 2 diabetes - teachings from the TOSCA.IT study. 2018 , 28, 722-726	1
1087	[Diabetes Mellitus Type 2: Recent Publications and New Drugs]. 2018 , 143, 772-776	0
1086	MANAGEMENT OF ENDOCRINE DISEASE: Which metabolic procedure? Comparing outcomes in sleeve gastrectomy and Roux-en Y gastric bypass. 2018 , 179, R77-R93	6
1085	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. 2018 , 20, 2255-2263	39
1084	Relationship Between Glycated Hemoglobin and Stroke Risk: A Systematic Review and Meta-Analysis. 2018 , 7,	40
1083	Antithrombotic Therapy for Peripheral Artery Disease: Recent Advances. 2018 , 71, 2450-2467	27
1082	Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide. 2018 , 137, 2200-2202	6
1081	A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks. 2018 , 41, 1121-1124	34
1080	Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction. 2018 , 20, 39	15
1079	Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?. 2018 , 19, 773-777	4
1078	Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes. 2018 , 20, 2238-2245	12
1077	Tratamiento de la diabetes tipo 2. 2018 , 22, 1-7	0
1076	Hispidulin alleviates high-glucose-induced podocyte injury by regulating protective autophagy. 2018 , 104, 307-314	23
1075	Improved Glycemic Control With Minimal Change in Medication Regimen Complexity in a Pharmacist-Endocrinologist Diabetes Intense Medical Management (DIMM) "Tune Up" Clinic. 2018 , 52, 1091-1097	2

1074	Update on Endothelin Receptor Antagonists in Hypertension. 2018 , 20, 51	12
1073	Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations. 2018 , 35, 939-965	7
1072	Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus. 2018 , 9, 1369-1375	2
1071	GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. 2018 , 1864, 2814-2821	60
1070	Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition. 2018 , 3, 1030-1038	15
1069	Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial. 2018 , 41, 1510-1515	13
1068	Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. 2018 , 28, 23-32.e3	49
1067	Économie du diabète : quelles perspectives ?. 2018 , 12, 190-193	
1066	Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. 2018 , 71, 2360-2372	186
1065	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. 2018 , 137, 2179-2183	52
1064	Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial). 2018 , 25, 512-520	14
1063	Diabetes mellitus and cardiovascular risk: Update of the recommendations of the Diabetes and Cardiovascular Disease working group of the Spanish Diabetes Society (SED, 2018). 2018 , 30, 137-153	8
1062	Typ-2-Diabetes à l'Update 2018. 2018 , 14, 294-308	1
1061	Insuffisance cardiaque et diabète : la nouvelle pandémie sous-estimée, mal connue, qui ne peut être ignorée plus longtemps. 2018 , 12, 182-189	
1060	Persistance et durabilité de l'efficacité du liraglutide : au-delà des études randomisées. 2018 , 12, 279-283	
1059	Implications of cardiovascular outcome trials with injectable antidiabetic agents. 2018 , 10, 801-803	0
1058	Herzinsuffizienz bei Diabetes. 2018 , 14, 384-392	
1057	ZP2495 Protects against Myocardial Ischemia/Reperfusion Injury in Diabetic Mice through Improvement of Cardiac Metabolism and Mitochondrial Function: The Possible Involvement of AMPK-FoxO3a Signal Pathway. 2018 , 2018, 6451902	9

1056	Cardiac Autonomic Neuropathy as a Result of Mild Hypercaloric Challenge in Absence of Signs of Diabetes: Modulation by Antidiabetic Drugs. 2018 , 2018, 9389784	17
1055	New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists. 2018 , 131, 1304-1306	4
1054	GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes. 2018 , 2018, 4020492	51
1053	Are We Ready to Bell The Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes. 2018 , 138, 4-6	11
1052	Nonsynonymous Variants in and Are Associated With Type 2 Diabetes in an East Asian Population. 2018 , 67, 1892-1902	23
1051	Hormonal Therapy in the Treatment of Chronic Heart Failure. 2018 , 508-516	0
1050	2020 vision - An overview of prospects for diabetes management and prevention in the next decade. 2018 , 143, 101-112	22
1049	Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists. 2018 , 143, 88-100	28
1048	Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain. 2018 , 35, 1605-1612	5
1047	Physicians' real-world experience with IDegLira: results of a European survey. 2018 , 6, e000531	10
1046	The Impact of Glycated Hemoglobin (HbA) on Cardiovascular Disease Risk: A Mendelian Randomization Study Using UK Biobank. 2018 , 41, 1991-1997	34
1045	Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials. 2018 , 35, 899-927	1
1044	Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality. 2018 , 122, 981-984	4
1043	Oral diabetes medication monotherapy and short-term mortality in individuals with type 2 diabetes and coronary artery disease. 2018 , 6, e000516	4
1042	Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. 2018 , 15, 465-468	15
1041	New therapies for acute myocardial infarction: current state of research and future promise. 2018 , 14, 329-342	5
1040	Histones and heart failure in diabetes. 2018 , 75, 3193-3213	14
1039	Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure. 2018 , 20, 2653-2660	8

1038	Evaluation of the HbA1c Reduction Cut Point for a Nonglycemic Effect on Cardiovascular Benefit of Hypoglycemic Agents in Patients with Type 2 Diabetes Based on Endpoint Events. 2018 , 2018, 8457538	2
1037	Evolution of Glucose-Lowering Drugs for Type 2 Diabetes. 2018 , 431-454	2
1036	Beyond Glucagon-like Peptide-1: Is G-Protein Coupled Receptor Polypharmacology the Path Forward to Treating Metabolic Diseases?. 2018 , 1, 3-11	17
1035	Managing Diabetes by Maintaining Healthier Beta Cells: A Fresh Perspective for Diabetes Educators. 2018 , 6, 12-18	4
1034	Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis. 2018 , 123, 704-713	31
1033	Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes. 2018 , 19, 1087-1095	9
1032	Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics. 2018 , 203, 30-38	29
1031	Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review. 2018 , 2018, 1025893	13
1030	Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients. 2018 , 20, 65	6
1029	Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment. 2018 , 18, 48	20
1028	The Cardiac Natriuretic Peptide System. 2018 , 163-171	1
1027	Renal effects of sacubitril/valsartan in patients with diabetes. 2018 , 6, 519-521	4
1026	Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: A meta-analysis of cardiovascular outcomes trials. 2018 , 143, 34-42	5
1025	Blood Glucose Management of Type 2 Diabetes in the Older People. 2018 , 12, 170-174	5
1024	Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes. 2018 , 52, 1224-1232	3
1023	Hypoglycemia Among Patients with Type 2 Diabetes: Epidemiology, Risk Factors, and Prevention Strategies. 2018 , 18, 53	62
1022	Clinical assessment and treatment of diabetes in patients with chronic kidney disease. 2018 , 218, 305-315	0
1021	Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL. 2018 , 114, e70-e71	5

1020	Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms. 2018 , 33, 197-210	2
1019	Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis. 2018 , 168, 170-178	19
1018	Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review. 2018 , 72, 1845-1855	121
1017	Peripheral Artery Disease. 2018 , 2159-2167.e2	
1016	The present and future treatment of pediatric type 2 diabetes. 2018 , 13, 207-212	1
1015	Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease. 2018 , 315, F1406-F1415	16
1014	Interactive effect of acute and chronic glycemic indexes for severity in acute ischemic stroke patients. 2018 , 18, 105	6
1013	Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. 2018 , 41, 2136-2146	51
1012	Medicaid Eligibility Expansions May Address Gaps In Access To Diabetes Medications. 2018 , 37, 1200-1207	15
1011	Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke. 2018 , 20, 145-166	22
1010	Diabetes and the Kidney. 2018 , 1-27	
1009	Glycemic Targets and Prevention of Chronic Complications. 2018 , 1-31	
1008	Diabetes mellitus tipo 2 y cardiopatía isquémica: fisiopatología, regulación glicémica y futuras opciones terapéuticas. 2018 , 37, 42-54	
1007	In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER. 2018 , 168, JC46	
1006	Cardiovascular effects of sodium glucose cotransporter 2 inhibitors. 2018 , 11, 133-148	15
1005	Beware of early drug intolerance in secondary prevention of cardiovascular disease. 2018 , 4, 202-204	
1004	Liraglutide relieves cardiac dilated function than DPP-4 inhibitors. 2018 , 48, e13007	12
1003	Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential. 2018 , 155, 264-274	23

1002	Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes. 2018 , 10, 413-421	7
1001	CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. 2018 , 34, 1350-1361	2
1000	The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. 2018 , 41, 2229-2235	40
999	Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. 2018 , 41, 1844-1853	43
998	Type 2 Diabetes. 2018 , 116-121	1
997	Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets. 2018 , 5, 1	59
996	Vascular Senescence in Cardiovascular and Metabolic Diseases. 2018 , 5, 18	104
995	Use of Readily Accessible Inflammatory Markers to Predict Diabetic Kidney Disease. 2018 , 9, 225	20
994	Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach. 2018 , 18, 64	19
993	Down-regulation of vascular GLP-1 receptor expression in human subjects with obesity. 2018 , 8, 10644	12
992	A Low-Protein Diet for Diabetic Kidney Disease: Its Effect and Molecular Mechanism, an Approach from Animal Studies. 2018 , 10,	21
991	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. 2018 , 24, 91-120	321
990	HbA1c method performance: The great success story of global standardization. 2018 , 55, 408-419	18
989	Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults. 2018 , 41, 1998-2009	24
988	Shared Genetic Contribution of Type 2 Diabetes and Cardiovascular Disease: Implications for Prognosis and Treatment. 2018 , 18, 59	15
987	Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. 2018 , 16, 116	28
986	Prediabetes and macrovascular disease: Review of the association, influence on outcome and effect of treatment. 2018 , 55, 6-11	11
985	Making sense of newer treatment options for type 2 diabetes. 2018 , 48, 762-769	

984	Glucagon-like peptide-1 receptor antagonism impairs basal exercise capacity and vascular adaptation to aerobic exercise training in rats. 2018 , 6, e13754	6
983	Non-insulin pharmacological therapies for treating type 1 diabetes. 2018 , 19, 947-960	8
982	MANAGEMENT OF ENDOCRINE DISEASE: Critical review of the evidence underlying management of glucocorticoid-induced hyperglycaemia. 2018 , 179, R207-R218	25
981	Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide. 2018 , 41, e133-e135	12
980	SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials. 2018 , 18, 63	9
979	Managing the Diabetic Kidney Patient. 2018 , 14, 526-530	
978	ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth. 2018 , 19 Suppl 27, 28-46	109
977	Cardiometabolic and Related Updates. 2018 , 52, 4-6	1
976	GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner. 2018 , 106, 83-90	12
975	Trends in Obesity and Risk of Cardiovascular Disease. 2018 , 5, 243-251	21
974	A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin. 2018 , 41, 1926-1937	34
973	HYPOGLYCEMIA IN THE ELDERLY WITH DIABETES: A GROWING PROBLEM WITH EMERGING SOLUTIONS. 2018 , 24, 312-314	1
972	Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. 2018 , 17, 83	580
971	Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials. 2018 , 17, 85	15
970	SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. 2018 , 41, 1543-1556	99
969	Corrigendum to: The EHJ Editorial Board Meeting. 2018 , 39, 2389	
968	Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus. 2018 , 38, 2198-2206	31
967	Branched-Chain Amino Acids: The Metabolic Link Between Type 2 Diabetes Mellitus and Cardiovascular Disease?. 2018 , 11, e002182	

966	Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes. 2018 , 17, 53	11
965	Insulin therapy for type 2 diabetes - are we there yet? The d-Nav ² story. 2018 , 4, 8	4
964	Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases. 2018 , 104, 257-268	8
963	Diabetes and cardiovascular mortality: the impact of sex. 2018 , 6, 517-519	10
962	Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study. 2018 , 44, 361-367	13
961	The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important?. 2018 , 12, 383-392	6
960	Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. 2018 , 17, 8	72
959	Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. 2018 , 17, 9	27
958	The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial. 2018 , 17, 65	26
957	Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. 2018 , 17, 30	15
956	Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism. 2018 , 17, 48	22
955	Diabetes, cardiovascular disease and the microcirculation. 2018 , 17, 57	162
954	The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin. 2018 , 17, 59	20
953	Konservative Therapie der Adipositas. 2018 , 22, 106-111	2
952	Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. 2018 , 20, 2309-2313	18
951	The European Medicines Agency's approval of new medicines for type 2 diabetes. 2018 , 20, 2059-2063	12
950	Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial. 2018 , 9, 1253-1267	11
949	Liraglutide attenuates the migration of retinal pericytes induced by advanced glycation end products. 2018 , 105, 7-13	6

948	Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. 2018 , 122, 1439-1459	148
947	Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years. 2018 , 9, 1279-1293	5
946	Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study. 2018 , 4, 11	13
945	The Alchemist's Nightmare: Might Mesenchymal Stem Cells That Are Recruited to Repair the Injured Heart Be Transformed Into Fibroblasts Rather Than Cardiomyocytes?. 2018 , 137, 2068-2073	15
944	Proneurotensin Predicts Cardiovascular Disease in an Elderly Population. 2018 , 103, 1940-1947	14
943	Cardiovascular Disease and Diabetic Kidney Disease. 2018 , 38, 217-232	36
942	No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials. 2018 , 34, e3061	9
941	Catalase and nonalcoholic fatty liver disease. 2018 , 470, 1721-1737	26
940	Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review. 2018 , 132, 1699-1709	32
939	Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. 2018 , 5, 1035-1043	16
938	Selecting appropriate weight loss pharmacotherapies in older adults to reduce cardiovascular risk. 2018 , 19, 1399-1402	3
937	Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy. 2018 , 67, 2410-2419	26
936	The treatment of type 2 diabetes in heart failure. 2018 , 35, 123-126	2
935	2018 ESC/ESH Guidelines for the management of arterial hypertension. 2018 , 39, 3021-3104	3698
934	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , 2018 , 379, 1107-1117	59.2 143
933	Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data. 2018 , 17, 118	18
932	Cardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events. 2018 , 12, 591	49
931	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. 2018 , 138, 1605-1607	20

930	The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. 2018 , 62, 535-545	9
929	Goals of Therapy. 2018 , 227-233	1
928	New pharmacological approaches for cardiovascular risk. 2018 , 151, 145-147	
927	GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side. 2018 , 315, F1519-F1525	22
926	Inpatient Glycemic Management in the Setting of Renal Insufficiency/Failure/Dialysis. 2018 , 18, 75	11
925	An interesting cross-talk between the glucagon-like peptide-1 receptor axis and angiotensin receptor pathway for modulation of renal sodium handling in obesity. 2018 , 41, 784-786	1
924	Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. 2018 , 6, 813-822	20
923	GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS. 2018 ,	
922	Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm. 2018 , 9, 1959-1968	1
921	The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes. 2018 , 41, 1259-1267	9
920	SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. 2018 , 61, 2134-2139	32
919	The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications. 2018 , 67, 1710-1719	50
918	Should Metformin Be First-line Therapy for Patients With Type 2 Diabetes and Chronic Kidney Disease?: Informed Patients Should Decide. 2018 , 178, 911-912	2
917	Diabetes and the Cardiovascular System. 2018 , 1-29	
916	Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. 2018 , 61, 1724-1733	47
915	Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: A pooled analysis of three federally-funded randomized trials. 2018 , 277, 186-194	6
914	Leptin, cardiovascular diseases and type 2 diabetes mellitus. 2018 , 39, 1176-1188	112
913	The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes. 2018 , 9, 151-155	6

912	Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity. 2018 , 20, 2557-2564	15
911	Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial. 2018 , 20, 2565-2573	11
910	Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. 2018 , 41, 1663-1671	32
909	Genomic insights into the causes of type 2 diabetes. 2018 , 391, 2463-2474	64
908	Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. 2018 , 6, 605-617	245
907	Selected state of the art research in internal medicine, 2017. 2018 , 48, 619-623	
906	Impacts of tight multifactorial intervention in patients with type 2 diabetes: Implications from the Japan Diabetes Outcome Intervention Trial 3. 2018 , 9, 1022-1024	0
905	Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. 2018 , 41, 1783-1791	63
904	Endpoints in diabetes cardiovascular outcome trials. 2018 , 391, 2412	5
903	Dulaglutide and renal protection in type 2 diabetes. 2018 , 6, 588-590	11
902	Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells. 2018 , 13, e0198938	6
901	Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. 2018 , 13, e0191953	8
900	Towards more specific treatment for diabetic dyslipidemia. 2018 , 29, 307-312	10
899	Chronic Kidney Disease-Induced Insulin Resistance: Current State of the Field. 2018 , 18, 44	9
898	Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA. 2018 , 18, 45	21
897	Diabetes mellitus and cardiovascular risk: Update of the recommendations of the Diabetes and Cardiovascular Disease working group of the Spanish Diabetes Society (SED, 2018). 2018 , 30, 137-153	1
896	The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE mice by blocking monocyte/macrophage activation. 2018 , 14, 150-157	26
895	Metabolic Complications, Nutritional Deficiencies, and Medication Management Following Metabolic Surgery. 2018 , 5-33	1

894	Clinical pharmacology of glucagon-like peptide-1 receptor agonists. 2018 , 17, 333-350	26
893	Ever-Increasing Insulin-Requiring Patients Globally. 2018 , 20, S21-S24	28
892	Diabetes management before, during, and after bariatric and metabolic surgery. 2018 , 32, 870-875	11
891	A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide. 2018 , 14, 869-877	35
890	Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients. 2018 , 72, 314-322	6
889	Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. 2018 , 57, 1529-1538	13
888	Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities. 2019 , 70, 197-209	10
887	Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. 2019 , 43, 136-145	26
886	Diabetes-related cardiomyopathy: The sweet story of glucose overload from epidemiology to cellular pathways. 2019 , 45, 238-247	27
885	Treatment: New Drugs. 2019 , 464-472	
884	Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. 2019 , 21, 84-94	41
883	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. 2019 , 21, 188-193	20
882	Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon-like peptide-1 receptor agonists. 2019 , 10, 408-417	7
881	Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach. 2019 , 21, 43-51	11
880	Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease. 2019 , 39, 122-127	1
879	GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells. 2019 , 26, 183-197	12
878	Effect of metformin on blood pressure in patients with hypertension: a randomized clinical trial. 2019 , 63, 252-258	5
877	Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. 2019 , 21, 252-260	25

876	New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs. 2019 , 104, 2463-2472	10
875	Cause-specific risk of major adverse cardiovascular outcomes and hypoglycemic in patients with type 2 diabetes: a multicenter prospective cohort study. 2019 , 63, 44-51	5
874	Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials. 2019 , 21, 3-14	29
873	Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts. 2019 , 194, 132-144	24
872	Management of type 2 diabetes in renal disease—the twilight of the gods. 2019 , 34, 231-233	
871	Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial. 2019 , 21, 2694-2703	13
870	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. 2019 , 7, 776-785	522
869	The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes. 2019 , 62, 364-369	9
868	Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study. 2019 , 21, 2651-2659	8
867	Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials. 2019 , 30, 578-589	29
866	IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy. 2019 , 21, 2643-2650	5
865	The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release. 2019 , 28, 1447-1454.e4	23
864	Type 2 diabetes: Why should diabetologists and cardiologists work more closely together?. 2019 , 45, 501-504	5
863	Coronary no-reflow in the modern era: a review of advances in diagnostic techniques and contemporary management. 2019 , 17, 605-623	6
862	Does glucagon-like peptide-1 induce diuresis and natriuresis by modulating afferent renal nerve activity?. 2019 , 317, F1010-F1021	10
861	Liraglutide Increases VEGF Expression CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury. 2019 , 10, 789	11
860	The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. 2019 , 6, 927-935	40
859	GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. 2019 , 66, 157-165	18

858	Kardiovaskuläres Management im neuen Therapiealgorithmus bei Typ-2-Diabetes. 2019 , 13, 49-49	
857	Clinical Predictors of the Need for Further Treatment Escalation in Patients with Type 2 Diabetes on Basal Insulin Therapy - A Retrospective Observational Study. 2019 , 127, 663-671	4
856	Mediation analysis of time-to-event endpoints accounting for repeatedly measured mediators subject to time-varying confounding. 2019 , 38, 4828-4840	18
855	Novel GLP-1 Analog Supaglutide Stimulates Insulin Secretion in Mouse and Human Islet Beta-Cells and Improves Glucose Homeostasis in Diabetic Mice. 2019 , 10, 930	3
854	What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?. 2019 , 10, 1719-1731	3
853	National ambulatory care non-insulin antidiabetic medication prescribing trends in the United States from 2009 to 2015. 2019 , 14, e0221174	9
852	Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice. 2019 , 36, 2895-2909	11
851	Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs. 2019 , 5, 27-30	4
850	Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases. 2019 , 11,	7
849	Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. 2019 , 42, 1912-1920	19
848	The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date. 2019 , 13, 2985-2996	6
847	Eine diabetische Nephropathie bestimmt die Diabetestherapie mit. 2019 , 13, 31-36	
846	Aspirin and Primary Prevention in Patients with Diabetes-A Critical Evaluation of Available Randomized Trials and Meta-Analyses. 2019 , 119, 1573-1582	3
845	Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program. 2019 , 10, 1893-1907	0
844	GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials. 2019 , 21, 2576-2580	73
843	[Therapy of diabetes mellitus in patients with chronic kidney disease]. 2019 , 144, 1044-1050	
842	Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. 2019 , 13, 849-866	24
841	The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes. 2019 , 34, 106-116	8

840	Diabetes and stroke. 2019 , 36, 126-131	0
839	Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis. 2019 , 2019, 1534365	11
838	GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals. 2019 , 18, 91	2
837	The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States. 2019 , 2, e00076	14
836	Blood glucose and hypertension development: the hen and egg controversy. 2019 , 37, 11-12	2
835	Hispanic representation in diabetes cardiovascular outcomes trials. 2019 , 7, e000656	5
834	Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features. 2019 , 39, 805-819	32
833	Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects. 2019 , 11, 938-948	16
832	Hipertensi3n arterial en la enfermedad renal cr3nica. 2019 , 12, 4772-4778	1
831	GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials. 2019 , 67-68, 110524	1
830	2018 ESC/ESH Guidelines for the management of arterial hypertension. 2019 , 72, 160.e1-160.e78	8
829	Patients with healed diabetic foot ulcer represent a cohort at highest risk for future fatal events. 2019 , 9, 10325	15
828	Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. 2019 , 10, 2040622319862691	25
827	Diabetes and the Cardiovascular System. 2019 , 1-29	
826	Approaches to Risk Assessment Among Older Patients With Diabetes. 2019 , 19, 59	8
825	The future of new drugs for diabetes management. 2019 , 155, 107785	18
824	Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. 2019 , 21, 2450-2458	6
823	Meta-analysis of metabolic surgery versus medical treatment for macrovascular complications and mortality in patients with type 2 diabetes. 2019 , 15, 1197-1210	13

822	Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease. 2019 , 40, 1080-1091	38
821	Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?. 2019 , 10, 1625-1643	
820	Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. 2019 , 21, 2474-2485	19
819	Why Do Patients With Well-Controlled Vascular Risk Factors Develop Progressive Chronic Kidney Disease?. 2019 , 35, 1170-1180	3
818	Heart Failure: Complications of Type 2 Diabetes. 2019 , 20, 1	
817	Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. 2019 , 288, 60-66	23
816	Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial. 2019 , 37, 335-343	1
815	Prevalence of pre-existing dysglycaemia among inpatients with acute coronary syndrome and associations with outcomes. 2019 , 154, 130-137	3
814	Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis. 2019 , 21, 2274-2283	17
813	Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea. 2019 , 40, 63-71	4
812	Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus. 2019 , 19, 54	4
811	Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes. 2019 , 99, 25-31	8
810	SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice. 2019 , 10, 1595-1622	24
809	Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer-Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study. 2019 , 42, 1675-1683	37
808	Urinary nucleic acid oxidation product levels show differential associations with pharmacological treatment in patients with type 2 diabetes. 2019 , 53, 694-703	4
807	A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor. 2019 , 20,	9
806	Weight Loss and Hypertension in Obese Subjects. 2019 , 11,	27
805	Clinical aspects of heart failure in individuals with diabetes. 2019 , 62, 1529-1538	9

804	Impact of FDA-Required Cardiovascular Outcome Trials on Type 2 Diabetes Clinical Study Initiation From 2008 to 2017. 2019 , 2168479019860122	2
803	Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives. 2019 , 17, 238	44
802	The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists. 2019 , 10, 2042018819865398	12
801	Cardiac Insulin Resistance in Heart Failure: The Role of Mitochondrial Dynamics. 2019 , 20,	19
800	Use of Insulin in the Inpatient Setting: Need for Continued Use. 2019 , 19, 64	3
799	Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease. 2019 , 21, 100	3
798	Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes. 2019 , 10, 1869-1878	15
797	Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development. 2019 , 215, 178-186	5
796	Modeling the Budgetary Impact of Payer Utilization Management Strategies: An Adapted Framework Based on Lessons Learned. 2019 , 25, 922-926	
795	Debate on Insulin vs Non-insulin Use in the Hospital Setting-Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?. 2019 , 19, 65	30
794	Cost-benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand. 2019 , 11, 423-430	1
793	Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. 2019 , 10, 1645-1717	17
792	Amelioration of perivascular adipose inflammation reverses vascular dysfunction in a model of nonobese prediabetic metabolic challenge: potential role of antidiabetic drugs. 2019 , 214, 121-143	17
791	Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. 2019 , 50, 193-203	62
790	Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities. 2019 , 79, 1187-1197	8
789	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. 2019 , 21, 38	
788	Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK. 2019 , 36, 1063-1071	7
787	DPP-4 Inhibition and the Path to Clinical Proof. 2019 , 10, 376	36

786	Incidence and Prevalence of Microvascular and Macrovascular Diseases and All-cause Mortality in Type 2 Diabetes Mellitus: A 10-year Study in a US Commercially Insured and Medicare Advantage Population. 2019 , 41, 1522-1536.e1	5
785	Proof of concept: Effect of GLP-1 agonist on food hedonic responses and taste sensitivity in poor controlled type 2 diabetic patients. 2019 , 13, 2489-2494	10
784	SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. 2019 , 12, 1001-1012	15
783	Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications. 2019 , 10, 324-332	9
782	Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry. 2019 , 6, 784-792	27
781	Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations. 2019 , 21, 2354-2367	16
780	Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study. 2019 , 8, e012244	8
779	Management of Diabetes Mellitus in Normal Renal Function, Renal Dysfunction and Renal Transplant Recipients, Focusing on Glucagon-Like Peptide-1 Agonist: A Review Based upon Current Evidence. 2019 , 20,	4
778	Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators. 2019 , 370, 447-458	17
777	The role of Glucagon-Like Peptide 1 Loading on periprocedural myocardial infarction During elective PCI (GOLD-PCI study): A randomized, placebo-controlled trial. 2019 , 215, 41-51	4
776	Incretin Therapies: Current Use and Emerging Possibilities. 2019 , 515-529	
775	A Hierarchical Peptide-Lanthanide Framework To Accurately Redress Intracellular Carcinogenic Protein-Protein Interaction. 2019 , 19, 7918-7926	12
774	Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction. 2020 , 41, 882-889	11
773	Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes. 2019 , 18, 135	6
772	Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: An implication in the treatment of atherosclerosis. 2019 , 116, 73-79	20
771	NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?. 2019 , 30, 891-902	42
770	Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. 2019 , 76, 1739-1748	10
769	The Use of Social Media in Pediatric Urology-Forging New Paths or Crossing Boundaries?. 2019 , 20, 72	1

768	Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis. 2019 , 16, e1002942	30
767	Sustained release and pharmacologic evaluation of human glucagon-like peptide-1 and liraglutide from polymeric microparticles. 2019 , 36, 747-758	7
766	Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis. 2019 , 10, 2183-2199	16
765	Liraglutide improves vascular dysfunction by regulating a cAMP-independent PKA-AMPK pathway in perivascular adipose tissue in obese mice. 2019 , 120, 109537	22
764	Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease. 2019 , 10, 2153-2167	12
763	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. 2019 , 74, 1926-1942	19
762	Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis. 2019 , 10, 2321-2330	5
761	SEA 2022 Standards for Global Control of Cardiovascular Risk.. 2022 ,	0
760	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology.. 2022 , 24, 143-168	7
759	The role of inflammation as a preponderant risk factor in cardiovascular diseases.. 2022 ,	0
758	Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.. 2021 ,	0
757	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. 2021 , 36, 108101	2
756	The prime type 2 diabetes model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus.. 2022 , 1-32	0
755	Informing and Empowering Patients and Clinicians to Make Evidence-Supported Outcome-Based Decisions in Relation to SGLT2 Inhibitor Therapies: The Use of the Novel Years of Drug administration (YoDa) Concept.. 2022 , 42, 113-125	1
754	Liraglutide, a glucagon-like peptide-1 receptor agonist, induces ADAM10-dependent ectodomain shedding of RAGE via AMPK activation in human aortic endothelial cells.. 2022 , 292, 120331	0
753	Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational study.. 2022 , 14, 100308	1
752	Diabetic neuropathy: Molecular approach a treatment opportunity.. 2022 , 143, 106954	2
751	Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy.. 2022 , 1	

750	The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury.. 2022 , 21, 18	
749	GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice.. 2022 , 34, 418-440	0
748	Redefining diabetes mellitus treatments according to different mechanisms beyond hypoglycaemic effect.. 2022 ,	
747	Effect of a three-week treatment with GLP-1 receptor agonists on vasoactive hormones in euvolemic participants.. 2022 ,	0
746	Association of Diabetes Duration and Glycemic Control With Stroke Rate in Patients With Atrial Fibrillation and Diabetes: A Population-Based Cohort Study.. 2022 , 11, e023643	1
745	Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations.. 2022 , 15, 281-295	7
744	SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes.. 2022 , 24, 183	1
743	Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021). 2022 ,	
742	Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure.. 2022 , 11, e022376	1
741	Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiovascular and Renal Outcomes: A Meta-Analysis and Meta-Regression Analysis.. 2022 ,	2
740	Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease.. 2022 , 12,	0
739	Understanding the restrictions in the prescription and use of potentially beneficial diabetes medications associated with low socio-economic status.. 2022 , 14, 100318	0
738	Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.. 2022 , 185, 109231	0
737	Anti-inflammatory Strategies in Atherosclerosis.. 2021 , 41, 433-442	4
736	Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. 2021 , 2, e214182	9
735	Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: a Pooled Analysis of SUSTAIN 6 and LEADER Trials.. 2021 ,	3
734	New Horizons A New Paradigm for Treating to Target with Second-Generation Obesity Medications. 2021 ,	5
733	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022.. 2022 , 45, S144-S174	46

732	11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022.. 2022 , 45, S175-S184	15
731	Impact of Obesity in Kidney Diseases.. 2021 , 13,	2
730	Influence of GLP-1 receptor agonist on insulin dosage and blood glucose control of patients with type 2 diabetes mellitus. 2021 , 13, 11814-11823	
729	Increased prevalence of cardiovascular risk factors in newly diagnosed type 2 diabetes patients - a retrospective study.. 2021 , 17, 331-336	
728	Cardiovascular effects of GLP-1 receptor agonism. 2022 ,	1
727	Diabetische Nephropathie. 2022 , 32-41	
726	Research Progress of Slimming Products and Their Pharmacological Mechanisms. 2022 , 11, 73-79	
725	Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.. 2022 , 8, e12268	1
724	Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities.. 2022 , 1	0
723	Drug-induced metabolic alterations in adipose tissue - with an emphasis in epicardial adipose tissue. 2022 , 94,	
722	Hypoglycemic Therapies and Reducing CVD Risk. 2022 , 193-210	
721	Obesity and Diabetes. 2022 , 1-61	
720	Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.. 2022 , 9, 793203	1
719	Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report.. 2022 , 13, 847778	
718	Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.. 2022 , 13, 389	0
717	Comparative Effects of Weight Loss and Incretin-Based Therapies on Endothelial Vasodilatory and Fibrinolytic Function.	
716	Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus.. 2022 , 37, 26-37	1
715	2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care.. 2022 ,	0

714	Low Use of Guideline Recommended Cardiorenal Protective Antihyperglycemic Agents in Primary Care: A Cross-Sectional Study of Persons with Type 2 Diabetes. 2022,	0
713	Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.. 2022,	9
712	Diabetes mellitus and heart failure: an update on pathophysiology and therapy.. 2022,	1
711	Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?. 2022, 16, 824054	1
710	Contemporary Medical Therapies for Patients with Peripheral Artery Disease and Concomitant Type 2 Diabetes Mellitus: a Review of Current Evidence.. 2022, 1	0
709	Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study.. 2022, 13, 453	4
708	Advances in Phenotyping Obesity and in Its Dietary and Pharmacological Treatment: A Narrative Review.. 2022, 9, 804719	1
707	Gastrointestinal Incretins-Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease-State of the Art.. 2022, 11,	2
706	The efficacy of pioglitazone for renal protection in diabetic kidney disease.. 2022, 17, e0264129	0
705	Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.. 2022,	
704	Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study.. 2022, 17, e0262831	1
703	Individuelle kardiovaskuläre Risiken der Patientin in der Lebensmitte. 2022, 25, 19-30	
702	Exenatide Once Weekly for Management of Type 2 Diabetes: A Review.. 2022, 14, 19-26	
701	Finding the undiagnosed: should we screen for diabetes pre-operatively?. 2022,	0
700	Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review.. 2022, 11,	3
699	Time-series analysis of recent antihyperglycemic medication prescribing trends for a diverse sample of Medicare enrollees with type 2 diabetes mellitus in an integrated health system.. 2022,	
698	Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial. 2022, 3,	
697	Role of Primary Care Clinicians in the Management of Patients With Type 2 Diabetes and Cardiorenal Diseases.	

696	Comparison of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists for atrial fibrillation in type 2 diabetes mellitus: systematic review with network meta-analysis of randomised controlled trials.. 2021 , 79,	1
695	Diabetes Mellitus and the Heart.. 2022 ,	0
694	GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art.	0
693	What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review.. 2022 ,	1
692	Preventing all-cause hospitalizations in type-2 diabetes with SGLT2 inhibitors and GLP-1 receptor agonists - narrative review and clinical approach.. 2022 ,	0
691	Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes.. 2022 , 12,	1
690	Metabolomics of Multimorbidity: Could It Be the ?. 2022 , 9, 848971	
689	Premature Death in Kidney Transplant Recipients: The Time for Trials is Now.. 2022 ,	0
688	Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.. 2022 , 13, 838410	2
687	Renal outcomes associated with glucose-lowering agents: Systematic review and meta-analysis of randomized outcome trials.. 2021 ,	
686	Wolfram Syndrome 1: From Genetics to Therapy.. 2022 , 19,	7
685	GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events.. 2022 , 13, 856111	2
684	Effects of GLP-1RAs on cardiovascular outcomes in patients with type 2 diabetes mellitus: review of real-world data on target populations from diabetes registry in Russian Federation. 2022 , 25, 61-71	
683	Implementation of Cardiometabolic Centers and Training Programs.. 2022 , 1	
682	GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions.. 2022 , 41, 136-149	0
681	Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.. 2022 ,	1
680	Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction.. 2022 , 8, e10	
679	Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.. 2022 , 5, e221169	1

- 678 GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease.. **2022**, 1
- 677 Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy.. **2022**, 2022, 3366109
- 676 Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss.. **2022**, 21, 36 1
- 675 Review article: Role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.. **2022**, 1
- 674 Adjunctive Therapy, Including Pharmacotherapy. **2022**, 279-296
- 673 Retrospective evaluation of microalbuminuria and GFR levels of diabetic patients taking DPP-4 Inhibitor, GLP-1 Analog, or SGLT-2 Inhibitor.
- 672 Effects of Antidiabetic Drugs on Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis.. **2022**, 13, 818537 0
- 671 Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors.. **2022**, 23, 1
- 670 INDY as a Therapeutic Target for Cardio-Metabolic Disease.. **2022**, 12,
- 669 The Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in China: Results from the Cross-Sectional CAPTURE Study.. **2022**, 1 0
- 668 SOP Der herzkranke Diabetespatient. **2022**, 18, 13-18 0
- 667 Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyses from the REASON Trial.. **2022**, 15, 685-694
- 666 Cardiorenal outcomes with ertugliflozin by baseline glucose-lowering agent: An analysis from VERTIS CV.. **2022**, 0
- 665 Protecting the Kidneys: Update on Therapies to Treat Diabetic Nephropathy.
- 664 Comparison of New Glucose-Lowering Drugs on Risk of Pancreatitis in Type 2 Diabetes: A Network Meta-Analysis.. **2021**, 0
- 663 Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials.. **2022**, 45, 1007-1012 0
- 662 The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients.. **2022**, 11, 0
- 661 Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis.. **2022**, 12, 5129 1

660	Trends in clinical characteristics and factors associated with initial prescription of SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus. 1	
659	A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study).. 2022, 36, 108188	0
658	Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS).. 2022, 13, 795	1
657	U-Shaped Associations Between Body Weight Changes and Major Cardiovascular Events in Type 2 Diabetes Mellitus: A Longitudinal Follow-up Study of Over 1.5 Million Nationwide Cohort.. 2022,	4
656	Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis.. 2022, 12,	
655	Epicardial adipose tissue in contemporary cardiology.. 2022,	12
654	Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists.. 2022, STROKEAHA121038151	0
653	The Impact of Obesity on Sudden Cardiac Death Risk.. 2022, 1	0
652	High pericoronary adipose tissue attenuation on computed tomography angiography predicts cardiovascular events in patients with type 2 diabetes mellitus: post-hoc analysis from a prospective cohort study.. 2022, 21, 44	2
651	Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India.. 2022, 16, 102436	0
650	Exploring molecular targets in diabetic kidney disease.. 2022,	1
649	Lipidomic Analysis Reveals the Protection Mechanism of GLP-1 Analogue Dulaglutide on High-Fat Diet-Induced Chronic Kidney Disease in Mice.. 2021, 12, 777395	0
648	Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients with Type 2 Diabetes.. 2022,	0
647	Predictors of Clinical Inertia and Type 2 Diabetes: Assessment of Primary Care Physicians and Their Patients.. 2022, 19,	0
646	The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis.. 2022, 109824	0
645	Age- and sex-specific trends in the incidence of myocardial infarction in Denmark, 2005 to 2021.. 2022, 346, 63-67	1
644	Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists.. 2022, 2022, 4554996	1
643	Effect of metformin on microvascular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.. 2022, 109821	0

642	Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis.. 2022,	1
641	Liraglutide preserves CD34 stem cells from dysfunction Induced by high glucose exposure.. 2022, 21, 51	0
640	Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes.. 2022,	0
639	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.. 2022, 21, 50	1
638	A Glucagon-like Peptide 1 Analogue Protects Mitochondria and Attenuates Hypoxia-reoxygenation Injury in Cultured Cardiomyocytes.. 2021, 79,	0
637	Bibliometric and Visualized Analysis of 2011-2020 Publications on Physical Activity Therapy for Diabetes.. 2022, 9, 807411	0
636	Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.. 2022, 22, 93	1
635	Knowledge Domain and Emerging Trends of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Research: A Bibliometric Analysis.. 2022, 101194	0
634	Cardiovascular events and atherosclerosis in patients with type 2 diabetes and impaired glucose tolerance -What are the medical treatments to prevent cardiovascular events in such patients?. 2022,	0
633	Novel drugs in pharmacotherapy of obesity. 2021, 17, 74-80	
632	SGLT2i agonist and GLP-1 receptor COMBination therapy in type 2 diabetes: Protocol for a KIDney endpoints real world study-[COMBi-KID Study] (Preprint).	
631	Why do SGLT2 Inhibitors Act as Cardio-renal Protective even in Non-diabetics?. 2021, 52, 157-164	
630	Typ-2-Diabetes: Gewichtsreduktion per stufenweiser Eskalation.	
629	A diabetic patient at the urological clinic. 2021, 22, 195-202	
628	J-curve relationship between long term glycemic control and mortality in diabetic patients with acute myocardial infarction undergoing percutaneous coronary intervention.. 2021, 20, 234	1
627	Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future.. 2021, 1	3
626	Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.. 2021, 20, 237	2
625	2021 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk. 2021, 22, 259-267	1

624	Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study.. 2021 , 9,	2
623	Optimal Type 2 Diabetes Mellitus Management and Active Ageing. 2021 , 2, 523-539	0
622	Three new categories of hypoglycaemic agents and various cardiovascular diseases: A meta-analysis.. 2021 ,	0
621	Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type 2 diabetes.. 2021 , 68, 741-750	
620	Adding liraglutide to diet and exercise to maintain weight loss - is it worth it?. 2021 , 1-5	
619	SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality.. 2021 , 8, 791311	1
618	Pharmacotherapy of obesity in complex diseases. 2021 , e12497	1
617	Cardiorenal benefits of glucagon-like peptide-1 analogues vs. exenatide analogues in patients with type 2 diabetes: a meta-analysis based on cardiovascular outcome trials.. 2021 ,	0
616	Can we cure diabetic kidney disease? Present and future perspectives from a nephrologist's point of view.. 2021 ,	3
615	Glycated hemoglobin as a surrogate for evaluating the effectiveness of drugs in diabetes mellitus trials: a systematic review and trial-level meta-analysis.. 2021 , 38, e12	0
614	Neurovascular Impairment and Therapeutic Strategies in Diabetic Retinopathy.. 2021 , 19,	4
613	Liraglutide Improves Cognitive and Neuronal Function in 3-NP Rat Model of Huntington's Disease.. 2021 , 12, 731483	2
612	Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts. 2021 ,	
611	Early Worsening of Retinopathy in Type 1 and Type 2 Diabetes After Rapid Improvement in Glycaemic Control: A Systematic Review.. 2021 , 13, 1	0
610	Phosphorus Supplementation Mitigates Perivascular Adipose Inflammation-Induced Cardiovascular Consequences in Early Metabolic Impairment. 2021 , e023227	1
609	The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.. 2021 , 2021, 6573369	
608	2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea. 2021 , 22, 244-249	3
607	Patient-Centered Diabetes Care of Cancer Patients.. 2021 , 21, 62	1

606	Management of Hyperglycemia in Older Adults with Type 2 Diabetes.. 2021 , 39, 39	1
605	Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients.. 2021 , 20, 235	0
604	Role of Diabetes Mellitus in Acute Coronary Syndrome Patients with Heart Failure and Midrange Ejection Fraction Who Have Undergone Percutaneous Coronary Intervention: A 3-Year Case-Series Follow-Up Retrospective Study.. 2021 , 14, 4931-4944	0
603	8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2022.. 2022 , 45, S113-S124	15
602	Survival of Patients Following First Diagnosis of Diabetic Foot Complications: A Nationwide 15-Year Longitudinal Analysis.. 2021 , 12, 801324	0
601	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 10th edition. 2022 , 24, 1-148	31
600	Obesity: Current Treatment Options in Adults. 2020 , 342-361	
599	Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS. 2022 , 527-553	
598	Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis.	
597	Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations.. 2022 ,	0
596	Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.. 2022 , 101161ATV0000000000000153	9
595	The Role of Mitochondrial Biogenesis Dysfunction in Diabetic Cardiomyopathy.. 2022 ,	0
594	Diabetes Medications and Cardiovascular Disease Prevention. 2022 , 12, 61-71	
593	Impact of Glucagon-Like Peptide 1 Receptor Agonists in Patients with Hemoglobin A1c of 9% or Greater.. 2022 , 8971900221087933	
592	Fibroblast Growth Factor 21 Levels Exhibit the Association With Renal Outcomes in Subjects With Type 2 Diabetes Mellitus.. 2022 , 13, 846018	0
591	Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.. 2022 , 1	2
590	Comparison of the Effectiveness of Liraglutide vs Semaglutide in a Veteran Population.. 2022 , 8971900221087127	
589	How do I diagnose Maturity Onset Diabetes of the Young (MODY) in my patients?. 2022 ,	0

588 Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers.. **2022**, 13, 786767 0

587 Die polyvaskuläre Erkrankung âeine Übersicht ber die Datenlage und Managementstrategien. **2022**, 11, 147-153

586 Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression - real-world clinical practice. 0

585 In vitro cell cultures of Brunner's glands from male mouse to study GLP-1 receptor function.. **2022**,

584 New Approaches to Diabetic Nephropathy from Bed to Bench.. **2022**, 10, 1

583 Effect of the Glucagon-Like Peptide-1 Receptor Agonists on Autonomic Function in Subjects with Diabetes: A Systematic Review and Meta-Analysis.. **2022**, 1

582 Table_1.docx. **2020**,

581 Table_10.docx. **2020**,

580 Table_11.docx. **2020**,

579 Table_12.docx. **2020**,

578 Table_13.docx. **2020**,

577 Table_2.docx. **2020**,

576 Table_3.docx. **2020**,

575 Table_4.docx. **2020**,

574 Table_5.docx. **2020**,

573 Table_6.docx. **2020**,

572 Table_7.docx. **2020**,

571 Table_8.docx. **2020**,

570	Table_9.docx. 2020 ,	
569	Image_1.tif. 2019 ,	
568	Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus.. 2022 ,	
567	Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome.. 2022 ,	0
566	Energy metabolism homeostasis in cardiovascular diseases.. 2021 , 18, 1044-1057	1
565	Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases.. 2022 , 13, 468-490	
564	Liraglutide ameliorates myocardial damage in experimental diabetic rats by inhibiting pyroptosis via Sirt1/AMPK signaling.. 2021 , 24, 1358-1365	1
563	Diabetes Mellitus. 2022 , 7017-7043	
562	Correlations Between Renal Biomarkers and the Treatment Outcomes in Diabetes: Ophthalmic Aspects. 2022 , 1-24	
561	Semaglutide Treatment Attenuates Vessel Remodelling in ApoE ^{-/-} Mice Following Vascular Injury and Blood Flow Perturbation.	
560	Management of hypercholesterolemia in individuals living with HIV/AIDS. 2022 , 999-1020	
559	Metformin Protects against Diabetic Cardiomyopathy: An Association between Desmin and α -B-crystallin Injury and the iNOS/mTOR/TIMP-1 Fibrosis Axis. 2022 , 10, 984	3
558	Glucose-Lowering and the Risk of Cardiovascular Events With Antidiabetic Therapies: A Systematic Review and Additive-Effects Network Meta-Analysis.. 2022 , 9, 876795	
557	Pharmacology. 2022 ,	
556	Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER.. 2022 , 22, 111	0
555	Oral semaglutide - Rybelsus [®] , the first GLP-1 receptor agonist for oral use in clinical practice. 2022 , 68, 89-95	
554	Macrovascular Complications. 2022 ,	0
553	Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.. 2022 , 21, 63	2

552	Trends in Use of High-Cost Antihyperglycemic Drugs Among US Adults with Type 2 Diabetes.. 2022 , 1	
551	Factors Associated with Weight Loss in People with Overweight or Obesity Living with Type 2 Diabetes Mellitus: Insights from the Global DISCOVER Study.. 2022 ,	
550	Heterogeneous treatment effects of intensive glycemic control on major adverse cardiovascular events in the ACCORD and VADT trials: a machine-learning analysis.. 2022 , 21, 58	0
549	Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics.. 2022 ,	1
548	Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds.. 2022 , 14, 319-332	0
547	Nano-Technological Approaches for Targeting Kidney Diseases With Focus on Diabetic Nephropathy: Recent Progress, and Future Perspectives. 2022 , 10,	0
546	Novel Drugs for Diabetes Also Have Dramatic Benefits on Hard Outcomes of Heart and Kidney Disease.. 2022 ,	1
545	Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: a nationwide cohort study.. 2022 ,	0
544	Individualized Glycemic Goals for Older Adults Are a Moving Target.. 2022 , 45, 1029-1031	0
543	Recent advances in the pharmacotherapeutic management of diabetic kidney disease.. 2022 , 23, 791-803	0
542	Secondary Prevention of Atherosclerotic Cardiovascular Disease. 2022 , 475-482	
541	Liraglutide treatment attenuates inflammation markers in the cardiac, cerebral and renal microvasculature in streptozotocin-induced diabetic rats.. 2022 , e13807	0
540	Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations.. 2022 ,	1
539	The Time-varying Cardiovascular benefits of Glucagon like peptide-1 receptor agonist therapy in patients with type 2 Diabetes Mellitus: Evidence from large multinational trials.. 2022 ,	0
538	Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a population-based cohort study.. 2022 ,	0
537	Diabetic cardiomyopathy and inflammation: development of hostile microenvironment resulting in cardiac damage. 2022 , 70,	1
536	American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).. 2022 , 28, 528-562	16
535	The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus.. 2022 , 11,	0

534	Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease.. 2022 ,	2
533	Microvascular disease increases the risk of lower limb amputation - a Western Danish cohort study.. 2022 , e13812	0
532	Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.. 2022 , 22, 125	1
531	A novel strategy for production of liraglutide precursor peptide and development of a new long-acting incretin mimic.. 2022 , 17, e0266833	1
530	The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.. 2022 , 1	
529	Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.. 2022 , 21, 64	0
528	Beneficial effects of sodium glucose co-transporter 2 inhibitors (SGLT2i) on heart failure and cardiovascular death in patients with type 2 diabetes might be due to their off-target effects on cardiac metabolism. 2016 , 11, 2-5	3
527	HDL and Diabetes.. 2022 , 1377, 119-127	
526	The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice.. 2022 , 1-13	
525	Breakthroughs in therapies for NASH and remaining challenges.. 2022 , 76, 1263-1278	1
524	Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN).. 2022 ,	0
523	Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study).. 2022 , 12, e056885	0
522	Precision Medicine for Diabetes and Cardiovascular Disease. 2022 , 53-64	
521	Precision Medicine for Diabetes and Dyslipidemia. 2022 , 65-87	
520	Precision Medicine Approaches for Management of Type 2 Diabetes. 2022 , 1-52	
519	Hypertension in Children with Type 2 Diabetes or the Metabolic Syndrome. 2022 , 1-18	
518	Plasma proteomics reveals an improved cardio-metabolic profile in patients with type 2 diabetes post-liraglutide treatment. 2022 , 19, 147916412210943	2
517	Management of Diabetic Nephropathy. 2022 , 671-690	

516	Exposure-Response Analysis of Cardiovascular Outcome Trials With Incretin-Based Therapies. 2022 , 13,	0
515	Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective. 2022 , 14, 1180	
514	Adipositas – eine behandlungsbedürftige chronische Erkrankung. 2022 , 147, 656-662	0
513	Emulating the GRADE Trial Using Real-World Data.	
512	Conocimiento del cardiólogo clínico sobre diabetes mellitus tipo 2 de alto riesgo. ¿Qué sabemos y cómo podemos mejorar?. 2022 ,	0
511	Terapia farmacologica dell'obesità: attualità e prospettive future.	
510	Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. 2022 , 11, 1060	
509	Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease.	1
508	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus. 2022 , 18, 402-411	
507	The Risk of Cardiovascular Events in Individuals With Primary Glomerular Diseases. 2022 ,	2
506	Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes. 2022 , 12,	0
505	Semaglutide treatment attenuates vessel remodelling in ApoE ^{-/-} mice following vascular injury and blood flow perturbation. 2022 ,	
504	Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.	0
503	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association.	8
502	Pharmacokinetic and pharmacodynamic studies of supaglutide in rats and monkeys. 2022 , 175, 106218	0
501	Gut Microbes in Cardiovascular Diseases. 2022 , 237-248	
500	A review of oral semaglutide available evidence: A new era of management of diabetes with peptide in a pill form. 2022 , 26, 98	1
499	A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health. 2022 , Publish Ahead of Print,	1

498	Non-Alcoholic Steatohepatitis Drug Development Pipeline: An Update.	0
497	Anthropomorphic Character Animations Versus Digital Chalk Talks in a Resident Diabetes Pharmacotherapy Curriculum: a Randomized Controlled Trial.	0
496	Persistent disparities in diabetes medication receipt by socio-economic disadvantage in Australia.	0
495	Status and Trends of the Association Between Diabetic Nephropathy and Diabetic Retinopathy From 2000 to 2021: Bibliometric and Visual Analysis. 13,	0
494	Efficacy and Safety of Once-Weekly Efglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.	0
493	Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies. 2022 , 12, e057977	0
492	New Hypoglycemic Drugs: Combination Drugs and Targets Discovery. 13,	1
491	Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease.	0
490	Optimizing the Use of Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes: Executive Summary.	
489	Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities. 2022 , 23, 6500	0
488	Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice. 13,	1
487	Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent. 2022 , 10-21	0
486	Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease.	2
485	Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus—choice determined by metabolic phenotype.	3
484	SIRP—Mediates IGF1 Receptor in Cardiomyopathy-Induced by Chronic Kidney Disease.	1
483	Pharmacological Management of Obesity: A Century of Expert Opinions in Cecil Textbook of Medicine. Publish Ahead of Print,	
482	GLP-1-Rezeptoragonisten und Modulation des kardiovaskulären Risikos. 2022 , 22, 35-37	
481	Therapie des Typ-2-Diabetes.	0

480	Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus. 2022,	0
479	Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias. 1-6	0
478	Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. 2022,	3
477	Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease.	0
476	Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis. 2022, 50, 101510	0
475	Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases. 2022, 152, 113236	0
474	Bioactive spermidine nanoparticles for effective cardiovascular recovery and diabetic therapy. 2022 , 446, 137353	0
473	Effectiveness and clinical benefits of new anti-diabetic drugs: A real life experience. 2022, 17, 1203-1215	0
472	Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity. 2022, 18, 43	
471	Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. 2022, 18, 10	1
470	SEA 2022 standards for the comprehensive control of cardiovascular risk. 2022, 34, 130-179	
469	The Effects of Diabetes and Glycemic Control on Cancer Outcomes in Individuals With Metastatic Breast Cancer.	0
468	Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States. 1-11	0
467	Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. 2022, 23, 7261	0
466	Cardiometabolism: Newer Pharmacologic Strategies for Reducing Cardiovascular Disease Risks.	
465	New Therapeutic Options for Type 2 Diabetes Mellitus and Their Impact Against Ischemic Heart Disease. 13,	
464	The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. 2022, 21,	2
463	A Retrospective Observational Study Examining the Generalizability of Glucagon-Like Peptide 1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with Type 2 Diabetes in Spain: The REPRESENT Study.	1

- 462 Assessing non-white ethnic participation in type 2 diabetes mellitus randomized clinical trials: A Meta-Analysis.
- 461 GLP-1 Receptor Agonists. **2022**, 130-160
- 460 Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?. **2022**, 37, 415-429 ○
- 459 DUAL I China: Improved glyceimic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs. **2022**, 14, 401-413
- 458 The 2021â2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD. **2022**, 14, ○
- 457 Appetite Control Mechanisms and Obesity. **2022**, 23, 89-96
- 456 Recent Advances in Anti-Obesity Drugs. **2022**, 23, 113-127 1
- 455 The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes. 1-13 1
- 454 Diabetes mellitus und Herz.
- 453 Diagnosis and Management of Heart Disease. **2022**, 139-172
- 452 New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies. 2
- 451 Therapy of Type 2 Diabetes. ○
- 450 Post-pancreatitis diabetes mellitus: insight on optimal management with nutrition and lifestyle approaches. **2022**, 54, 1776-1786 1
- 449 Part Three: A Brief Primer of Non-Insulin Treatments for Type 2 Diabetes Mellitus in Older People. **2022**, 37, 251-259 1
- 448 Diabetes Mellitus. **2022**, 395-406
- 447 Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials). **2022**,
- 446 Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials. 13, ○
- 445 Exercise Augments the Effect of SGLT2 Inhibitor Dapagliflozin on Experimentally Induced Diabetic Cardiomyopathy, Possible Underlying Mechanisms. **2022**, 12, 635 ○

444	AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. 2022,	6
443	Mind the Gap: Addressing Cardiovascular Disease in Chronic Obstructive Pulmonary Disease. 2022, 19, 1093-1095	
442	Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors.	0
441	Diabetes in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators. 2022, 23, 7886	
440	Epicardial Adipose Tissue: A Novel Potential Imaging Marker of Comorbidities Caused by Chronic Inflammation. 2022, 14, 2926	1
439	Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes â a systematic review and meta-analysis. 2022, 108255	1
438	Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.	
437	Effect of Liraglutide Treatment on Whole Body Glucose Fluxes in C-peptide Positive Type 1 Diabetes During Hypoglycaemia.	
436	Use of sodium-glucose co-transporter 2 inhibitors, changes in body mass index and risk of fracture: a population-based cohort studyâ 2022, 109993	
435	Obesity and Chronic Kidney Disease A Current Review.	1
434	Cardiovascular complications of diabetes. 1-6	0
433	Effect of glucagon-like peptide-1 (GLP-1) analogues on epicardial adipose tissue: A meta-analysis. 2022, 16, 102562	2
432	Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial. 2022,	1
431	An investigation of physicians' prescribing behaviors related to antidiabetic agents for Type 2 diabetes mellitus patients and associated factors in Taiwan. 1-19	
430	Progress in the management of patients with diabetes and chronic kidney disease. 2022, 31, 456-463	
429	Clinical Characteristics of Inpatients With New-Onset Diabetes Mellitus in Eastern China: Based on Novel Clustering Analysis. 13,	0
428	GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease. 2022, 2, 386-398	
427	Compound dietary fiber and high-grade protein diet improves glycemic control and ameliorates diabetes and its comorbidities through remodeling the gut microbiota in mice. 9,	0

426 Update on the management of diabetes in long-term care facilities. **2022**, 10, e002705

425 Herz und Diabetes.

424 Twenty-Year Temporal Trends in Risk of Ischemic Stroke in Incident Type 2 Diabetes: A Danish Population-Based Cohort Study. ○

423 Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria. **2022**, 10, e002806 ○

422 Case report of an angiosarcoma of the abdominal wall during liraglutide injections: A coincidence?. **2022**, 97, 107444 ○

421 The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice. **2022**, 13, 204201882211124 ○

420 Pharmacologic treatment of obesity. **2022**, 65, 408-416

419 Optimization of trial duration to predict long-term HbA1c change with therapy: a pharmacometrics simulation-based evaluation.

418 Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives. Volume 18, 753-760 ○

417 Severe hypoglycemia as a risk factor for cardiovascular outcomes in patients with type 2 diabetes: is it preventable?. **2022**, 4, 106-113

416 Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report?.

415 Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. ○

414 Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis. 13,

413 Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease. **2022**, 17, e0273004 ○

412 Diabetes subtypes classification for personalized health care: A review. ○

411 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. **2022**, 38, 1153-1167 1

410 The role of insulin and incretin-based drugs in biliary tract cancer: epidemiological and experimental evidence. **2022**, 13,

409 Gut immune cells—a novel therapeutical target for cardiovascular disease?. 9,

- 408 The Effect of SGLT-2 inhibitors and GLP-1RA on Major Cardiovascular Conditions: A Meta-Analysis.
- 407 Induced Human Regulatory T Cells Express the Glucagon-like Peptide-1 Receptor. **2022**, 11, 2587 0
- 406 Endothelial Glycocalyx. 1-31 1
- 405 Pharmacotherapy in obesity: the current state and the near future. **2022**, 65, 514-531
- 404 Non-Immunologic Causes of Late Death-Censored Kidney Graft Failure: A Personalized Approach. **2022**, 12, 1271
- 403 Benefits of Adding Glucagon-Like Peptide 1 Receptor Agonists to Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetic Patients With Atherosclerotic Disease and Heart Failure. **2022**, 1
- 402 Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective. 1
- 401 Four-Year Report on Renal Outcomes Following Elective Withdrawal of Long-Term RAAS Blockade in a Cohort of Patients with Otherwise Inexplicable New-Onset and Progressive Acute Kidney Injury.
- 400 Liraglutide protects against diastolic dysfunction and improves ventricular protein translation.
- 399 WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. **2022**, 8
- 398 Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. **2022**, 21, 0
- 397 Derivatization with fatty acids in peptide and protein drug discovery. 0
- 396 Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?.
- 395 New and developing pharmacotherapies for hypertension. **2022**, 20, 647-666 0
- 394 Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes. 2
- 393 Role of thermogenic adipose tissue in lipid metabolism and atherosclerotic cardiovascular disease: lessons from studies in mice and humans. 1
- 392 Reconsidering the role of glycemic control on cardiovascular disease risk in type 2 diabetes: A 21 st century assessment. 0
- 391 Modifying a Hydroxyl Patch in Glucagon-like Peptide 1 Produces Biased Agonists with Unique Signaling Profiles.

- 390 Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists. ○
- 389 Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update. **2022**, 11, 4660 ○
- 388 Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors. ○
- 387 Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives. **2022**, 10, 1989 1
- 386 Highlighting the Role of Obesity and Insulin Resistance in Type 1 Diabetes and Its Associated Cardiometabolic Complications. **2022**, 11, 180-202 1
- 385 Medical and Surgical Treatment of Obesity. **2022**,
- 384 Home-Measured Pulse Pressure Is a Predictor of Cardiovascular Disease in Type 2 Diabetes: KAMOGAWA-HBP Study. **2022**,
- 383 Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes. **2022**, 21,
- 382 The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis. **2022**, 38, 1201-1210 ○
- 381 Gasdermin D-mediated pyroptosis in myocardial ischemia and reperfusion injury: Cumulative evidence for future cardioprotective strategies. **2022**,
- 380 Novel polymorphism of HMGCR gene related to the risk of diabetes in premature triple-vessel disease patients.
- 379 Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study. **2022**, 11, 4938 ○
- 378 Agonistas del receptor de GLP-1 en el manejo del paciente con diabetes mellitus tipo 2. Una aproximación para el nefrólogo. **2022**,
- 377 Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs. **2022**,
- 376 DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits. **2022**, 9, ○
- 375 Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes. 1-3
- 374 Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists. **2022**, 153, 113517
- 373 Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group. **2022**, 365, 8-18 1

- 372 Beyond HbA1c cardiovascular protection in type 2 diabetes mellitus. 1-7 ○
- 371 Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study. ○
- 370 Sitagliptin reduces FAP-activity and increases intact FGF21 levels in patients with newly detected glucose abnormalities. **2022**, 556, 111738 ○
- 369 Modulatory role of gut microbiota in cholesterol and glucose metabolism: Potential implications for atherosclerotic cardiovascular disease. **2022**, 359, 1-12 ○
- 368 Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities. **2022**, 239, 108270 ○
- 367 Medical Management of Obesity. **2021**, 1-19 ○
- 366 Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie. **2022**, 211-225 ○
- 365 Herz und Diabetes. **2022**, 1-14 ○
- 364 Abordaje práctico de la semaglutida en el paciente con diabetes tipo 2. **2022**, 22, 1-9 ○
- 363 Comparison of the effects of exenatide and insulin glargine on right and left ventricular myocardial deformation as shown by 2D-speckle-tracking echocardiograms. **2022**, 25, 1094 ○
- 362 Minimizing Cardiometabolic Risk Factors in Patients with Acromegaly. **2022**, 261-273 ○
- 361 Glucagon Like Peptide-1: More than Glucose Control and Weight Reduction. ○
- 360 Noncardiovascular-derived therapeutic peptidomimetics in cardiovascular disease. **2022**, 615-654 ○
- 359 Strategies for participant retention in long term clinical trials: A participant centric approaches. **2022**, 0 ○
- 358 Under-utilisation of cardioprotective glucose-lowering medication in diabetics living with HIV. **2022**, ○
- 357 The Role of Perivascular Fat in the Diagnosis and Prognosis of Atherosclerosis. 3, ○
- 356 A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease. Volume 18, 889-900 ○
- 355 The Australian Obesity Management Algorithm: A simple tool to guide the management of obesity in primary care. **2022**, 4

- 354 Diabetic Cardiomyopathy: Pathophysiology and Novel Therapies. **2022**, 1, 0
- 353 The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes. 0
- 352 Tratamiento farmacológico del paciente que vive con diabetes mellitus tipo 2. **2022**, 36, 81-105 0
- 351 Phytosomes: A Novel Phytoconstituent Delivery Approach to Improve the Efficacy of Obesity Treatment. **2022**, 18, 0
- 350 Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 12
- 349 Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease. 0
- 348 Glycemia Reduction in Type 2 Diabetes – Microvascular and Cardiovascular Outcomes. **2022**, 387, 1075-1088 4
- 347 The potential of glucagon-like peptide-1 receptor agonists in heart failure. 13, 0
- 346 Approaching sleep apnea management in the setting of uncertainty. 0
- 345 Expert Opinion on Diabetes Management Challenges and Role of Basal Insulin/GLP-1 RA Fixed-Ratio Combination in People with Type 2 Diabetes from Indonesia. Volume 15, 2977-2990 0
- 344 Type 2 diabetes and cardiovascular disease: risk reduction and early intervention. 0
- 343 Kardiovaskuläre Prävention bei Diabetes mellitus Typ 2: Gewichtsreduktion beseitigt nicht das kardiale Risiko. 0
- 342 Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – April 2022 – AWMF Registration No.: 021-025. **2022**, 60, e733-e801 0
- 341 Correlations Between Renal Biomarkers and the Treatment Outcomes in Diabetes: Ophthalmic Aspects. **2023**, 411-434 0
- 340 Glucagon-like peptide 1 receptor agonists in heart failure: the need for a rewind. 0
- 339 Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 16
- 338 Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases. **2022**, 23, 10882 0
- 337 Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. **2022**, 12, 0

336	Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.	1
335	Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP -1 RAs) : A pooled analysis of type 2 diabetes trials.	0
334	Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.	0
333	Treatment of Diabetes and OsteoporosisâA Reciprocal Risk?. 2022 , 10, 2191	0
332	Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options. 2022 , 10, 2274	2
331	Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft f. Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) âApril 2022 â AWMF-Registernummer: 021â025. 2022 , 60, 1346-1421	0
330	Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease. 1-10	0
329	The societal impact of early intensified treatment in patients with type 2 diabetes mellitus. 00-00	0
328	A Reassessment of the Causal Effects of Dysglycemia on Atherosclerotic and Thrombotic Events. 2022 , 71, 2075-2077	0
327	ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents.	2
326	Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study. 13,	0
325	Nouveaux traitements du diabe de type 2 et rinopathie diabique. 2022 ,	0
324	Use of Glucose-Lowering Agents in Diabetes and Chronic Kidney Disease. 2022 ,	0
323	Letter regarding the article âDulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.	0
322	Gestational Diabetes MellitusâRecent Literature Review. 2022 , 11, 5736	2
321	Even high normal blood pressure affects live birth rate in women undergoing fresh embryo transfer.	0
320	Diabetic kidney disease treatment: new perspectives. 2022 , 41, S63-S73	1
319	Diabetes and cardiovascular risk according to gender: an overview of epidemiological data from the early Framingham reports to the cardiovascular outcomes trials. 2022 ,	0

- 318 Emulating the GRADE trial using real world data: retrospective comparative effectiveness study. e070717 ○
- 317 A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction. 9, ○
- 316 Obesity and diabetes in people of African ancestry with HIV. ○
- 315 Diabetic Kidney Disease Back in Focus: Management Field Guide for Health Care Professionals in the 21st Century. 2022, 97, 1904-1919 ○
- 314 First-Line Therapy for Type 2 Diabetes With Sodium-glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. 4
- 313 The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review. ○
- 312 Efficacy and safety of traditional chinese medicine treatment for overweight and obese individuals: A systematic review and meta-analysis. 13, ○
- 311 Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. 1
- 310 Long-Term Outcomes Among Young Adults With Type 2 Diabetes, Based on Durability of Glycemic Control: Results From the TODAY Cohort Study. ○
- 309 Cardiovascular disease management in Australian adults with type 2 diabetes: insights from the CAPTURE study. ○
- 308 Jerusalem artichoke inulin supplementation ameliorates hepatic lipid metabolism in type 2 diabetes mellitus mice by modulating the gut microbiota and fecal metabolome. ○
- 307 Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY study. 2022, 21, ○
- 306 Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?. 2022, 11, 6183 ○
- 305 Preoperative evaluation and perioperative management of patients undergoing major vascular surgery. 2022, 27, 496-512 ○
- 304 Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel. ○
- 303 Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists. 2022, 10, 2586 ○
- 302 Effects of GLP -1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and meta-analysis. ○
- 301 Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus – Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft ff. Angiologie (DGA), der Deutschen Gesellschaft ff. Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen Gesellschaft ff. Gefäßchirurgie und Gefäßmedizin (DGG). 2022, 17, S354-S364 ○

300	Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control. 2022 , 23, 12305	0
299	Diabetes mellitus und Herz. 2022 , 17, S323-S326	0
298	AWARE. A web application to rapidly assess cardiovascular risk in Type 2 Diabetes Mellitus..	0
297	The Profile of Glucose Lowering Therapy in Persons with Type 2 Diabetes Mellitus in an Aging Russian Population. 2022 , 12, 1689	0
296	Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare Insured Adults With CKD in the United States. 2022 , 100564	0
295	Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. 13,	1
294	Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics. 2022 , 5, e2237606	0
293	The Cardiovascular Benefits and Infections Risk of SGLT2i versus Metformin in Type 2 Diabetes: A Systemic Review and Meta-Analysis. 2022 , 12, 979	0
292	The effects and side effects of liraglutide as a treatment for obesity. 2022 , 4, 142-148	0
291	The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study. 10,	2
290	Comparative Effects of Weight Loss and Incretin-Based Therapies on Vascular Endothelial Function, Fibrinolysis, and Inflammation in Individuals with Obesity and Pre-Diabetes : A Randomized, Controlled Trial.	1
289	2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Patient-Centered Care. 2022 ,	0
288	COOrdinating CaRDiology CliNics RANdomized Trial of Interventions to Improve OutcomEs (COORDINATE) âDiabetes: Rationale and Design. 2022 ,	1
287	Diabetes mellitus im Alter. 2022 , 17, S226-S236	0
286	Safety and Efficacy of Liraglutide on Reducing Visceral and Ectopic Fat in Adults with or without Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.	0
285	An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes. 2022 , 58, 1475	0
284	The efficacy and safety of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists in pediatric patients with type 2 diabetes: a systematic review. 2022 ,	0
283	Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta-analysis. 2022 , 30, 2111-2121	1

282	KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. 2022 , 102, S1-S127	8
281	Cardiorenal disease management in type 2 diabetes: An expert consensus. 2022 , 102661	0
280	Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease. 13,	2
279	Knowledge domain and emerging trends in empagliflozin for heart failure: A bibliometric and visualized analysis. 9,	0
278	Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.	0
277	Prevalence of cardiovascular events among patients with type 2 diabetes in the west region of Saudi Arabia. 2022 ,	0
276	Glucose-responsive nanoparticles designed via a molecular-docking-driven method for insulin delivery. 2022 , 352, 527-539	0
275	Use of real-world evidence data to evaluate the comparative effectiveness of second-line type 2 diabetes medications on chronic kidney disease. 2022 , 30, 100309	0
274	Pharmacotherapy of type 2 diabetes: An update and future directions. 2022 , 137, 155332	3
273	Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis. 2022 , 54, 101697	0
272	The treatment of diabetes in advanced liver disease: Change of a paradigm. 2023 , 28, 100772	0
271	Cardiovascular Risk Factor Control in Type 2 Diabetes Mellitus and New Trial Evidence. 83-89	0
270	Editorâs Pick: How Can We Develop More Effective Strategies for Type 2 Diabetes Mellitus Prevention? A Paradigm Shift from a Glucose-Centric to a Beta Cell-Centric Concept of Diabetes. 46-52	0
269	Effects of GLP-1 Receptor Agonists on Cardiovascular Events and Their Clinical Positioning. 2021 , 110, 2458-2464	0
268	Inadequate Use of Newer Treatments and Glycemic Control by Cardiovascular Risk and Sociodemographic Groups in US Adults with Diabetes in the NIH Precision Medicine Initiative All of Us Research Program.	0
267	Assessment of Glucose Lowering Medicationsâ Effectiveness for Cardiovascular Clinical Risk Management of Real-World Patients with Type 2 Diabetes: Targeted Maximum Likelihood Estimation under Model Misspecification and Missing Outcomes. 2022 , 19, 14825	0
266	Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients. 2022 , 5, e2240117	0
265	Depot-specific adipose tissue modulation by SGLT2 inhibitors and GLP1 agonists mediates their cardioprotective effects in metabolic disease. 2022 , 136, 1631-1651	0

264	Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use. 2022 , 12, 1915	0
263	Hypertension management in patients with cardiovascular comorbidities.	0
262	Alogliptin and Heart Failure Outcomes in Patients With Type 2 Diabetes. 089719002211356	0
261	Gastric bypass versus best medical treatment for diabetic kidney disease: 5 years follow up of a single-centre open label randomised controlled trial. 2022 , 101725	1
260	Initiation of the Fixed Combination IDegLira in Patients with Type 2 Diabetes on Prior Injectable Therapy: Insights from the EASY French Real-World Study. 2022 , 13, 1947-1963	0
259	The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modeling of type 2 diabetes.	0
258	Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes.	0
257	Diabetic cardiomyopathy: a brief summary on lipid toxicity.	1
256	Successful conservative management of left ventricular assist device candidates.	0
255	Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure.	0
254	Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real-world clinical practice: 36 month post-marketing observational study.	0
253	Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches. 2022 , 14, 4801	0
252	Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity. 2022 , 155346	0
251	Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations. 2022 , 2022, 1-9	0
250	Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients. 2022 , 12, 1121	0
249	Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. 2022 , 21,	1
248	Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada. 2022 , 10, e002995	0
247	Liraglutide versus colesevelam for treating bile acid diarrhoea âAuthors' reply. 2022 , 7, 1075-1076	0

- 246 Liraglutide versus colesevelam for treating bile acid diarrhoea. **2022**, 7, 1075 ○
- 245 Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. **2022**, 18, 40-53 ○
- 244 Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence. **2022**, 27, 107424842211463 1
- 243 Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis. **2023**, 37, 108362 ○
- 242 Corrigendum to “Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes” [Biochem. Pharmacol. 206 (2022) 115304]. **2023**, 207, 115349 ○
- 241 Meta-Analysis on the Efficacy of Novel Glucose-Lowering Agents in Older Patients With Type 2 Diabetes Mellitus. **2023**, 187, 127-130 ○
- 240 Post-Transplant Diabetes Mellitus. **2022**, 391-401 ○
- 239 Le patient atteint de maladies cardiovasculaires. **2022**, 99-122 ○
- 238 The GLP-1 receptor agonists: what’s all the (cardiovascular) hype about?. **2022**, 3, 118-120 ○
- 237 Recomendaciones preventivas cardiovasculares. Actualizaci3n PAPPS 2022. **2022**, 54, 102444 ○
- 236 Emerging drugs for the treatment of diabetic nephropathy. **2022**, 27, 417-430 ○
- 235 Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9). **2022**, 46, 953-955 ○
- 234 Comparative evaluation new glucagon-like peptide 1 receptor agonist semaglutide and sodium-glucose cotransporter-2 inhibitors empagliflozin on left ventricular diastolic function in patients with arterial hypertension, obesity and type 2 diabetes mellitus. **2022**, 19, 39-48 ○
- 233 Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes. **2022**, 24, 925-937 ○
- 232 Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Prescribing in Patients With Diabetes Mellitus With and Without Cardiovascular Disease. **2022**, ○
- 231 The Impact of Cardiac Comorbidity Sequence at Baseline and Mortality Risk in Type 2 Diabetes Mellitus: A Retrospective Population-Based Cohort Study. **2022**, 12, 1956 ○
- 230 Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?. **2022**, 23, 14598 ○
- 229 Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. ○

228	The Gut-Bone Axis in Diabetes.	0
227	Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China.	0
226	Mechanisms of GLP-1 Receptor Agonists on the Cardio-Renal Protective Effects. 2022 , 53, 249-262	0
225	New therapies for obesity.	2
224	Liraglutide Improves the Angiogenic Capability of EPC and Promotes Ischemic Angiogenesis in Mice under Diabetic Conditions through an Nrf2-Dependent Mechanism. 2022 , 11, 3821	0
223	Pathophysiological Links Between Diabetes and Cardiovascular Diseases: at the Biochemical and Molecular Levels. 2022 , 191-229	0
222	Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications.	0
221	Glucocorticoids, stress and eating: The mediating role of appetite-regulating hormones.	1
220	Diabetic cardiomyopathy: Clinical phenotype and practice. 13,	1
219	Clinical Pharmacy Specialist Collaborative Management and Prescription of Diabetes Medications with Cardiovascular Benefit. 089719002211443	0
218	GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. 2022 , 146, 1882-1894	1
217	Tirzepatide and prevention of chronic kidney disease.	1
216	Managing Diabetes. 2022 ,	0
215	The Impact of Pharmacist Intervention to Improve Medication Access for Patients with Diabetes. 2022 ,	0
214	Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials. 2022 , 14,	0
213	Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis.	0
212	Sodium-Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study.	0
211	Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study. 2022 , 21,	0

- 210 Engineered probiotics *Clostridium butyricum* -pMTL007-GLP -1 improves blood pressure via producing GLP -1 and modulating gut microbiota in spontaneous hypertension rat models. ○
- 209 A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF -06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus. ○
- 208 Is this the end of intensified insulin therapy and obesity in light of updates with novel medicines?. **2022**, 1, 79-84 ○
- 207 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetesâ2023. **2023**, 46, S128-S139 ○
- 206 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetesâ2023. **2023**, 46, S158-S190 7
- 205 Disparities in Adoption of New Diabetic Therapies with Cardiovascular Benefits. **2022**, 110233 ○
- 204 Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin. **2022**, 15, 1569 ○
- 203 Therapeutics in Metabolic Diseases. **2023**, 255-273 ○
- 202 Liraglutide Lowers Endothelial Vascular Cell Adhesion Molecule-1 in Murine Atherosclerosis Independent of Glucose Levels. **2022**, ○
- 201 Coronary Atherosclerosis Burden and Progression to Guide Clinical Decision Making: A Report from the American College of Cardiology Innovations in Prevention Working Group. **2022**, ○
- 200 A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes. ○
- 199 Diab te de type 2 : prescriptions de traitements non appropri es et observance insuffisante remettent en cause les b n fices cardio-ri aux attendus. Un gouffre entre RCT, consensus d  xperts et vraie vie . **2022**, ○
- 198 One-year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes. ○
- 197 Mechanotransduction regulates inflammation responses of epicardial adipocytes in cardiovascular diseases. 13, ○
- 196 Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. 13, ○
- 195 Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis. 13, ○
- 194 Indikationsstellung in der Adipositastherapie âSurgeons first? // Indications in obesity therapy - surgeons first?. **2022**, 147, 525-538 ○
- 193 Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data. 13, ○

192	Renal outcomes with sodium-glucose cotransporters 2 inhibitors. 13,	o
191	Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen. 2022 , 27,	1
190	Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review. 2022 , 12,	o
189	Nationwide cardiovascular risk categorization: applying the European Society of Cardiology (ESC) guidelines to the Swedish National Diabetes Register.	o
188	11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetesâ2023. 2023 , 46, S191-S202	o
187	A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes.	o
186	Antidiabetic agents: Do they hit the right targets?. 2022 , 2, 225-243	o
185	Pharmacologic management of weight regain following bariatric surgery. 13,	o
184	Diabetes Mellitus at an Elderly Age.	o
183	Hypertension in Children with Type 2 Diabetes or the Metabolic Syndrome. 2023 , 421-437	o
182	Diabetes and Stroke: What Are the Connections?.	o
181	New Antidiabetic Agents: Relevance to Cardiovascular Outcomes. 2023 , 337-349	o
180	Bayesian design of multi-regional clinical trials with time-to-event endpoints.	o
179	Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus. 13,	o
178	Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review. 1358863X2211438	o
177	Alert-LDL-2: adherence to guidelines and goals attainment in the treatment of diabetic patients with dyslipidemia.	o
176	Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?. 2023 ,	o
175	Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs. 2023 , 13, 87	o

- 174 Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2. **2023**, 67-138 ○
- 173 46-Year-Old Woman With Type 2 Diabetes Mellitus and Obesity. **2023**, 98, 181-186 ○
- 172 Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: A retrospective cohort study. ○
- 171 The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. 1
- 170 Hypertension and Type 2 Diabetes. **2023**, 39-56 ○
- 169 Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. **2023**, 108389 ○
- 168 Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. **2023**, ○
- 167 The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic Patients. **2023**, 2023, 1-9 ○
- 166 Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology. **2023**, 153, 40004 ○
- 165 Control of Blood Glucose and Cardiovascular Risk Profile. **2023**, 451-469 ○
- 164 Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?. **2023**, 17, 102696 ○
- 163 Die Biomarker BNP und NT-proBNP. ○
- 162 Novel Therapeutics for Type 2 Diabetes, Obesity, and Heart Failure. **2023**, 43, 1-7 ○
- 161 Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: A narrative review. **2023**, 37, 108390 ○
- 160 Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. **2023**, 12, 145 ○
- 159 Multinational Patterns of Second-line Anti-hyperglycemic Drug Initiation Across Cardiovascular Risk Groups: A Federated Pharmacoepidemiologic Evaluation in LEGEND-T2DM. ○
- 158 Clinical spotlight intervention to accelerate translation of evidence-based practices in primary care. **2022**, 11, e002032 1
- 157 Cardiometabolic Effects of Empagliflozin in Patients Undergoing Elective Percutaneous Coronary Intervention for Type 2 Diabetes Mellitus. **2022**, 62, 64-72 ○

- 156 Optimizing antihypertensive therapy in patients with diabetes mellitus. ○
- 155 AWARE. A web application to rapidly assess cardiovascular risk in Type 2 Diabetes Mellitus.. ○
- 154 Gut microbiota mediates positive effects of liraglutide on dyslipidemia in mice fed a high-fat diet. 9, ○
- 153 The Common Single Cause of Chronic Multi-Hormonal Resistance in Oxidative Stress. **2023**, 12, 75 ○
- 152 Patients' Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Volume 16, 3415-3428 ○
- 151 Diabetes mellitus. **2022**, 267-285 ○
- 150 Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study. ○
- 149 Medications for the treatment of obesity. **2023**, ○
- 148 Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023. **2023**, 100056 1
- 147 Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. ○
- 146 Les traitements médicamenteux dans l'obésité. **2023**, ○
- 145 Factors associated with gastrointestinal side effects after liraglutide treatment for type 2 diabetes. 14, ○
- 144 Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry). **2023**, 13, e068652 ○
- 143 Short-Term Effects of Liraglutide versus Vildagliptin on Insulin Secretion and Sensitivity in Type 2 Diabetes: A Single Blinded Randomized Controlled Trial (LIRAVIS Study). **2023**, 13, 45-57 ○
- 142 The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease. ○
- 141 Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. **2023**, 47, 10-26 ○
- 140 Sustained Delivery of GLP-1 Receptor Agonists from Injectable Biomimetic Hydrogels Improves Treatment of Diabetes. ○
- 139 Medical therapy. **2023**, 353-361 ○

- 138 Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment. ○
- 137 Short-term effect of polyethylene glycol loxenate on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial. 14, ○
- 136 Medical Management of Obesity. **2023**, 63-81 ○
- 135 Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand. ○
- 134 Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. **2023**, 5, 1 2
- 133 Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis. **2023**, 22, ○
- 132 Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts. **2022**, 42, 519-530 ○
- 131 Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: pathophysiology and implications for cardiovascular disease. **2023**, 137-173 ○
- 130 The fundamental role of obesity management in cardiometabolic risk reduction: nonpharmacological, pharmacological, and surgical approaches. **2023**, 273-309 ○
- 129 Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice. **2023**, 11, 662 ○
- 128 Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study. **2023**, 33, 1017-1025^o
- 127 Current and emerging medications for the management of obesity in adults. **2023**, 218, 276-283 ○
- 126 The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms. **2023**, 69, 102355 ○
- 125 Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia/reperfusion injury. **2023**, 86, 101884 ○
- 124 The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009-2021. **2023**, 15, ○
- 123 Évolution de la stratégie thérapeutique hors insuline dans le diabète de type 2. **2023**, ○
- 122 Diabetes care among individuals with and without schizophrenia in three Canadian provinces: A retrospective cohort study. **2023**, 82, 19-25 ○
- 121 Linagliptin exacerbates heart failure due to energy deficiency via downregulation of glucose utilization and absorption in a mouse model. **2023**, 948, 175673 ○

120	Role of dysfunctional peri-organ adipose tissue in metabolic disease. 2023 , 212, 12-20	0
119	Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?. 9,	0
118	Excess body weight: Novel insights into its roles in obesity comorbidities. 2023 , 92, 16-27	0
117	Recent developments in adjunct therapies for type 1 diabetes. 2022 , 31, 1311-1320	0
116	Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care. 2023 , 25, 1331-1340	0
115	Blood glucose control with different treatment regimens in type 2 diabetes patients hospitalized with COVID-19 infection: A retrospective study. 2023 , 102, e32650	0
114	Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment. 2023 , 29, 139-150	0
113	Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).	0
112	Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.	0
111	Metabolic Control, Diabetic Complications and Drug Therapy in a Cohort of Patients with Type 1 and Type 2 Diabetes in Secondary and Tertiary Care between 2004 and 2019. 2023 , 20, 2631	0
110	Prevalence of type 2 diabetes complications and its association with diet knowledge and skills and self-care barriers in Tabriz, Iran: A cross-sectional study. 2023 , 6,	0
109	Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies. 2023 , 21,	0
108	GLP1 Promotes Cortical and Medullary Perfusion in the Human Kidney and Maintains Renal Oxygenation During NaCl Loading. 2023 , 12,	0
107	Vascular ageing: moving from bench towards bedside.	1
106	Liraglutide promotes angiogenesis in adipose tissue via suppression of adipocyte-derived IL-6. 2023 , 651, 8-19	0
105	Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond. 2023 , 38, 25-33	0
104	Ischemia with Nonobstructive Coronary Artery Disease and Atrial Cardiomyopathy—Two Sides of the Same Story?. 2023 , 13, 443	0
103	Urinary Proteome Differences in Patients with Type 2 Diabetes Pre and Post Liraglutide Treatment. 2023 , 45, 1407-1421	1

- 102 The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes. **2023**, 35, 253-273 ○
- 101 Hormonal GutâBrain Signaling for the Treatment of Obesity. **2023**, 24, 3384 ○
- 100 Obesity Pharmacotherapy: a Review of Current Practices and Future Directions. **2023**, 21, 27-47 ○
- 99 Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes. **2023**, 12, e0279 ○
- 98 Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia. **2023**, 12, 1382 ○
- 97 Interest and place of new therapeutic classes in the treatment of elderly diabetic patients. **2023**, 49, 101431 ○
- 96 Type 2 Diabetes Mellitus: Beyond the Beta Cell. 36-46 ○
- 95 Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies. 14, ○
- 94 Systematic investigation of the underlying mechanisms of GLP-1 receptor agonists to prevent myocardial infarction in patients with type 2 diabetes mellitus using network pharmacology. 14, ○
- 93 A Web-based Application for Risk Stratification and Optimization in Patients with Cardiovascular Disease (STOP-CVD): Pilot Study (Preprint). ○
- 92 Patterns of new glucagon-like peptide-1 receptor agonist use in patients with type 2 diabetes during 2014â2019 from a US database: prescriber and patient characteristics. **2023**, 15, 190-195 ○
- 91 GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ○
- 90 Very low-calorie ketogenic diet (VLCKD): an antihypertensive nutritional approach. **2023**, 21, ○
- 89 Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study. **2023**, 12, 1586 ○
- 88 Commentary on glucose reduction in type 2 diabetes (GRADE). ○
- 87 Long-term increase in fasting blood glucose is associated with increased risk of sudden cardiac arrest. **2023**, 22, ○
- 86 Therapieoptionen bei diabetischer Nephropathie. ○
- 85 Clinical characteristics of patients undergoing primary bariatric surgery in the United Kingdom based on the National Bariatric Surgery Registry. ○

- 84 The Evolution of Diabetes Treatment Through the Ages: From Starvation Diets to Insulin, Incretins, SGLT2-Inhibitors and Beyond. ○
- 83 Five-year Weight Loss Maintenance With Obesity Pharmacotherapy. ○
- 82 Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial. **2023**, 57, 101865 ○
- 81 Analysis of the Value of SGLT2i Combined with GLP-1RAs in Cardiovascular Benefit of Elderly T2DM Patients. **2023**, 13, 2736-2743 ○
- 80 The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study. **2023**, 37, 108436 1
- 79 Exercise in the Prevention and Treatment of Type 2 Diabetes. 4559-4585 ○
- 78 Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies. ○
- 77 Comparative cardiovascular effects of GLP -1 agonists using real-world data. ○
- 76 Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists. **2023**, 13, 100477 ○
- 75 Effect of Intensive Glycemic Control on Myocardial Infarction Outcome in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. **2023**, 2023, 1-11 ○
- 74 Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. 1
- 73 SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes. ○
- 72 Current treatment landscape for obesity in Singapore. **2023**, 64, 172 ○
- 71 Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry. ○
- 70 Targeting Glomerular Hemodynamics for Kidney Protection. **2023**, 30, 71-84 ○
- 69 Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes. **2023**, 25, 53-63 1
- 68 Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review. **2023**, ○
- 67 Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial. ○

- 66 Data-driven classification of health status of older adults with diabetes: The diabetes and aging study. ○
- 65 Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease. **2023**, ○
- 64 Paradigm shift of the medical care in diabetes. **2023**, 19, 32-41 ○
- 63 Demystifying the Progression of Retinopathy with Glucagon-Like Peptide-1 Receptor Agonists: Facts, Evidence, and Misperceptions. **2022**, 1, 53 ○
- 62 Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP. Volume 17, 791-806 ○
- 61 Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). 10, ○
- 60 Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes. 14, 188-197 ○
- 59 Glucagon-Like Peptide 1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice. **2023**, ○
- 58 CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. **2023**, 22, ○
- 57 The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease. **2023**, 22, ○
- 56 Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes. **2023**, 24, 5714 ○
- 55 Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes. **2023**, Publish Ahead of Print, ○
- 54 The protective roles of liraglutide on Kawasaki disease via AMPK/mTOR/NF- κ B pathway. **2023**, 117, 110028 ○
- 53 Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021. **2023**, 100617 ○
- 52 The Fat Kidney. ○
- 51 Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. **2023**, 22, ○
- 50 Epicardial adipocytes in the pathogenesis of atrial fibrillation: An update on basic and translational studies. 14, ○
- 49 An Investigation on the Efficacy of Glucagon-Like Peptide 1 Receptor Agonists Drugs in Reducing Urine Albumin-to-Creatinine Ratio in Patients With Type 2 Diabetes: A Potential Treatment for Diabetic Nephropathy. **2023**, ○

- 48 Diabetes and the Kidney. **2023**, 168-207 ○
- 47 Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. **2023**, 117-167 ○
- 46 Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. **2023**, 58, 101882 ○
- 45 Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL , a randomized trial. ○
- 44 Update on Medical Management of Diabetes. **2023**, ○
- 43 Adherence to cardiovascular prevention guidelines in an academic center. **2023**, ○
- 42 Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. **2023**, 22, ○
- 41 Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study. **2023**, 22, ○
- 40 Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register. ○
- 39 Lower-limb peripheral arterial disease and amputations in people with diabetes: Risk factors, prognostic value and management. **2023**, 52, 104164 ○
- 38 Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. ○
- 37 Current pharmacotherapy options in pediatric obesity. **2023**, 78, 122-126 ○
- 36 The expanding incretin universe: from basic biology to clinical translation. ○
- 35 Multiparametric magnetic resonance imaging: A robust tool to test pathogenesis and pathophysiology behind nephropathy in humans. ○
- 34 Risk of Lactic Acidosis in Hospitalized Diabetic Patients Prescribed Biguanides in Japan: A Retrospective Total-Population Cohort Study. **2023**, 20, 5300 ○
- 33 How cardiologists can manage excess body weight and related cardiovascular risk. An expert opinion. **2023**, ○
- 32 Glucagon-like peptide-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications. **2023**, 365-396 ○
- 31 Diabetes: evolution of multifactorial vascular risk reduction. **2023**, 311-335 ○

- 30 Management of diabetic kidney disease: where do we stand?: A narrative review. **2023**, 102, e33366 ○
- 29 Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus. ○
- 28 Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States. **2023**, ○
- 27 Early Insight Into the Retrospective Data of a Case Series on Type 2 Diabetes Mellitus on Alternate-Day Dosing of Oral Semaglutide: Utopia or Reality?. **2023**, ○
- 26 Embedding guidelines into clinical practice. **2023**, 40, 28 ○
- 25 Beyond the Cox Hazard Ratio: A Targeted Learning Approach to Survival Analysis in a Cardiovascular Outcome Trial Application. 1-27 ○
- 24 Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSD) for the treatment of type 2 diabetes mellitus (2023). **2023**, 153, 40060 ○
- 23 Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). **2023**, 22, ○
- 22 Metformin adherence and the risk of cardiovascular disease: a population-based cohort study. **2023**, 14, 204062232311631 ○
- 21 Treatment of Patients Chronic Coronary Heart Disease and Type 2 Diabetes Mellitus. **2023**, 13, 97-109 ○
- 20 GLP-1 receptor agonist, liraglutide, protects podocytes from apoptosis in diabetic nephropathy by promoting white fat browning. **2023**, ○
- 19 Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. **2023**, 8, ○
- 18 Semaglutide-eye-catching results. 14, 424-434 ○
- 17 GLP-1-Rezeptor-Agonisten: Für welche Personen mit Diabetes mellitus Typ 2?. **2023**, 112, 324-328 ○
- 16 The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus: A Systematic Review. **2023**, 24, 7184 ○
- 15 New Insights into the Use of Liraglutide: Impact on Cardiovascular Risk and Microvascular Outcomes. **2023**, 11, 1159 ○
- 14 Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects. **2023**, 185, 106448 ○
- 13 Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism. **2023**, 13, 1024 ○

- | | | |
|----|---|---|
| 12 | Treatment of type 2 diabetes patients with heart conditions. 1-11 | ○ |
| 11 | Pharmacological management of youth with type 2 diabetes and diabetic kidney disease: a comprehensive review of current treatments and future directions. 1-12 | ○ |
| 10 | Reduced incidence of cardiovascular disease in patients with type 2 diabetes through the integrated improvement of diabetes care by comparing two prospective observational cohorts in real-world clinical practice (JDDM 72). 2023 , 110674 | ○ |
| 9 | Recent advances in the treatment of patients with obesity and chronic kidney disease. 2023 , 55, | ○ |
| 8 | Hospital diabetes management (Update 2023). 2023 , 135, 242-255 | ○ |
| 7 | Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials. 2023 , 19, 14-27 | ○ |
| 6 | Treatment of type 2 diabetes. | ○ |
| 5 | Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz (Update 2023). 2023 , 135, 201-206 | ○ |
| 4 | Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK. 2023 , 14, 1005-1021 | ○ |
| 3 | COMBINSI (COMBat to INSufficient Insulin therapy) âA Portuguese project in type 2 diabetes. 2023 , 17, 102776 | ○ |
| 2 | Impact of polyethylene glycol loxenate on cardiovascular outcomes in patients with type 2 diabetes: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (BALANCE-3). 2023 , 13, e069080 | ○ |
| 1 | GLP-1 analogs and regional adiposity: A systematic review and meta-analysis. | ○ |